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ABSTRACT 
 
Introduction 
 
South Africa has the largest absolute number of individuals living with human 
immuno-deficiency virus (HIV) in the world. The quality assurance (QA) of HIV 
rapid diagnostic tests (RDT) has not kept pace with the rate of expanded testing 
and utilisation of RDT. This has made it difficult to assess the accuracy of testing. 
In South Africa HIV counselling and testing (HCT) and the use of HIV RDT is the 
point of entry to HIV prevention, management, care, treatment and support.  
 
HCT in public health facilities is delivered mainly through rapid testing by non-
professional staff. Implementation of QA processes is crucial for accurate 
diagnosis of HIV. However, accuracy of HCT using rapid test kits in non-laboratory 
settings in South Africa will remain a challenge unless there is evidence that non-
laboratory rapid HIV testing results are as reliable as the laboratory-based enzyme 
immunoassays. 
 
This study aimed to determine the accuracy of HIV RDT in the context of an 
intervention. The objectives of the study were: i. To assess the sensitivity and 
specificity of rapid test kits in two provinces; ii. To assess the sensitivity and 
specificity of rapid test kits between the two provinces and New Start non-
governmental organisation (NGO) which implemented a more comprehensive 
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quality management system (QMS); iii. To assess the accuracy of HIV RDT in the 
two provinces; iv. To assess the accuracy of HIV RDT between the two provinces 
and New Start sites.  
The hypothesis was ‘the accuracy of HIV diagnosis using HIV RDT kits in non-
laboratory settings in which an intervention has been introduced (internal quality 
control), also known as IQC, will not be different compared to settings that do not 
utilize IQC’.  
 
Methods 
 
In South Africa, the current laboratory-based gold standard for diagnosis of HIV 
infection in adults in the public sector as recommended by the National Health 
Laboratory Services (NHLS) Virology expert committee is a serial 2-test algorithm. 
Thus, a reactive enzyme immunoassay (EIA) test result must be confirmed by a 
second confirmatory EIA that must be different in terms of antigens and 
technology. The Expert Committee recommendation is that positive results should 
be confirmed by a separate sample 14 days later. In the case of HIV rapid testing 
the national HIV counselling and testing (HCT) policy, 2010, similarly recommends 
a serial 2-test algorithm for diagnosis where a reactive screening test is confirmed 
by a different confirmatory test. If the confirmatory test is reactive the diagnosis is 
positive. If test 1 is non-reactive then the diagnosis is negative. In case of 
discrepant results an enzyme-linked immunosorbent assay (ELISA) test was 
recommended as a tiebreaker. A new HIV testing services (HTS) policy was 
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approved in South Africa in 2016 and it further recommended that the first time 
discrepant results are found, the counsellor must repeat the algorithm and if on 
repeat, the results are still discrepant, then reflex testing is recommended where 
the blood (whole blood) of a client is taken to the laboratory for ELISA (NDOH, 
2016).This algorithm has replaced the use of Western Blot is South Africa. The 
rationale for the change was based on the sensitivity and specificity of 3rd and 4th 
generation ELISAs, workload, costs and expertise. 
 
With the introduction of the 3rd and latterly 4th generation EIA tests the above 
algorithm is in use in South Africa and has replaced the use of the Western blot as 
a confirmatory test. The rationale for the change is based on earlier detection of 
HIV infection, workload, costs and expertise. Further developments for a 
diagnostic algorithm include the use of a fourth generation test and if reactive to 
use a HIV-1 and HIV-2 discriminatory test and HIV viral load.  
 
This study was cross-sectional and compared the performance of HIV RDT in 
selected sites in Limpopo province that had introduced an intervention viz., an 
internal quality control (IQC) as part of quality management system (QMS) 
implementation, and compared to Mpumalanga province that had not introduced 
the IQC and performed limited QMS activities. The sample size calculated for the 
study was N = 717. IQC is an independent internal quality control that is used to 
check that an analytical phase or test precision is optimal. The introduction of 
routine QMS in Limpopo was through implementation of IQC supported by 
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appropriate training and certification of implementers. IQC was implemented 
routinely as part of the provincial QA initiatives with the aim of supporting the 
implementation of HIV RDT in non- laboratory settings. There are other QA 
measures that may be implemented to support HIV RDT programmes including 
external quality assessment (EQA) such as proficiency testing (PT) which is a tool 
used to assess the testing process independently. EQA implementation was 
however not part of the Limpopo (LP) QMS implementation. Six high volume 
testing sites comprising of 3 hospitals and 3 clinics were selected per province. 
This was to avoid the risk of not meeting the required number of participants due 
to refusals, lack of results and challenges with reporting.  
 
In order to mitigate risk, the study was oversampled, where a total of 457 
participants from the LP sites were enrolled in the study and results were analysed 
and compared to those of 361 participants from the Mpumalanga (MP) sites 
resulting in a total sample size of 818. The analyses included demographics, 
performance of RT as measured by the number of discordant results, reliability 
and validity of rapid tests RT as measured by the sensitivity, specificity, positive 
predictive value (PPV) and negative predictive value (NPV) results. The data 
between Limpopo and Mpumalanga were further analysed together with the data 
from selected sites from a non-governmental organisation (NGO) called New Start 
and the performance, reliability and validity of the HIV test results were compared. 
The main role of New Start was to offer HCT in support of the government 
priorities and it implemented several different QMS measures for HIV rapid testing, 
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namely, IQC, EQA, PT and re-testing, training for implementers, development and 
implementation of standard operating procedures (SOPs), and ensuring that all 
commodities were stored under appropriate conditions including temperature 
monitoring.  
 
In order to determine the validity and reliability of HIV RDT against the gold 
standard ELISA in Limpopo, Mpumalanga and New Start sites, the rate of 
discordance, the sensitivity, specificity, PPV and NPV were determined. Logistic 
regression models were constructed to assess the association between the 
interventions in the provinces. Crude and adjusted odds ratios were used as a 
measure of association between exposure and outcome and a 95% precision of 
estimate was used to ascertain statistical significance. Exposure factors with 
p<0.05 were considered statistically significant. 
 
Results 
 
A total of 947 attendees for HCT services in selected sites in Mpumalanga and 
Limpopo provinces between August and April 2012, were screened and of these, 
818 were enrolled into the study according to the study inclusion criteria. There 
was no significant difference (p=0.05) between the number of participants enrolled 
in Limpopo (457) as compared to Mpumalanga (361) though Limpopo enrolled 
more participants than Mpumalanga. All available data from New Start sites for the 
period 2008 was analysed. The gender, rate of discordance and HIV positivity rate 
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were significantly different between the two provinces (p<0.05). The study showed 
that the laboratory-based HIV prevalence rate in each setting was 22.9% in 
Limpopo, 26% in Mpumalanga and 11% in New Start sites. The prevalence rates 
reported by Shisana, 2014, were 21.8% for Mpumalanga and 13.9% for Limpopo.  
 
The rate of discordant HIV test results between the 2 provinces and New Start 
sites was also measured where discordant results were defined as those that were 
different between HIV rapid test and the ELISA test. The rate of discordant HIV 
test results was 5.9% (27) in Limpopo, 11.0% (40) in Mpumalanga p= 0.010 and 
1.4% (68) in New Start sites. False negative results accounted for all the 
discordant results.  
 
Logistic regression models were used to estimate the Odds Ratio (OR) and the 
95% confidence interval of the association between implementation of QA 
programme and the HIV test accuracy or the HIV discordance rate. Facilities 
without a QA intervention programme had an approximately 2-fold increased odds 
of HIV test discordance compared to facilities with a QA programme in place 
(crude OR 1.86, 95% CI: 1.10 – 3.12 and adjusted OR 1.90, 95% CI:1.08 - 3.30). 
This association was statistically significant. The sex and age of the participants 
was not associated with discordance rate.  
 
The sensitivities of the HIV RDT in Limpopo, Mpumalanga and New Start sites 
were 86% (CI: 83.9-89.4), 72% (CI: 64.2-79.0) and 98% (CI: 97.6-98.4) 
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respectively. In this study, specificity ranged within 99% (CI: 98.9-99.9) in all sites 
(Provinces and New Start sites). The PPV in Limpopo, Mpumalanga and New 
Start sites were 98% (CI: 93.2-99.6), 97% (CI: 91.0-99.2) and 93% (CI: 92.3-93.7) 
respectively, The NPV results in Limpopo were 93% (90.5-95.2), Mpumalanga at 
86% (CI:81.3-90.7). For New Start sites, the NPV was 99.6% (CI: 99.4-99.8). The 
sensitivities and specificities of the sites were used at a national prevalence rate of 
18.8% to determine the national PPV and NPV and these were found to be 100% 
(CI: 100-100) and 91.3% (CI: 89.04-92.96) respectively. 
 
Discussion 
 
In all three settings the World health Organisation (WHO) recommended sensitivity 
(>99%) and specificity (>98%) were not met. There was a gradient of sensitivities 
and specificities that was associated with the extent of QA implementation. Thus, 
New Start sites with a more extensive set of QA activities had the highest 
sensitivity; LP with introduction of IQC, had an intermediate sensitivity and MP the 
lowest. Despite the introduction of an intervention LP was not able to meet the 
required level of QA implementation compared to New Start. Increased 
discordance was associated with the extent of implementation of QA as shown by 
the results of the logistic regression model (crude and adjusted). In this study there 
was a decline in sensitivity that resulted in some false negative results. To a lesser 
extent, some false positive results were also identified in New Start sites. In the 
case of LP and MP the potential contributory factors to false negative results 
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would include the extent of QA implementation and training. Further evidence of 
the relative poor implementation would include the M&E assessments and in the 
course of the study there lost results, poorly taken and missing specimens that led 
to data being excluded.     
 
Conclusion 
 
On the basis of these results, it is concluded that implementation of quality 
assurance measures is critical to ensure correct diagnosis of rapid HIV testing. 
Furthermore, implementation of a combination of aspects of QA is urgently 
required including training of all implementing staff on quality assurance of rapid 
HIV testing, monitoring and evaluation to assess kit performance through IQC and 
PT, as well as implementation of the current South African HIV testing Services 
(HTS) Policy. All PT methods should be explored for implementation and training 
and certification of implementers must be ensured.  
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1 CHAPTER 1: INTRODUCTION 
 
1.1 Summary 
In this chapter, a general background of the global burden of HIV and acquired 
immune deficiency syndrome (AIDS) is provided. The chapter further explores the 
burden of HIV and AIDS in sub-Saharan Africa then finally in South Africa. The 
current rapid HIV diagnostic procedures and their challenges are explored. 
Justification of the study and critical review of the documented data on HIV rapid 
diagnostic tests (RDTs), QA measures including EQA methods, internal quality 
control (IQC) methods and retesting methods in non-laboratory settings are 
reviewed. The search strategy for literature review is articulated and the chapter 
ends with a description of the aims and objectives of the study. 
 
1.2 Search strategy for literature review 
 In terms of literature review, the following search strategies were used: On line 
search strategy and search engines, dates of publications, and search words 
strategy. 
 
1.2.1 On-line search 
A comprehensive search of biomedical databases was carried out to find all 
relevant manuscripts published in English. The search aimed at identifying 
relevant peer-reviewed studies that would provide adequate information on the 
study topic. Different sources of literature were utilised. These included peer 
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reviewed published literature from PUB med, published policies and guidelines, 
literature published on the internet and some grey literature that was relevant, well 
cited and published though not necessarily peer reviewed, and published reports.   
 
1.2.2 Search engines, dates of publications, and search words used 
Relevant search words were used to develop a data base, for example: 'quality 
assurance of HIV rapid test kits', ‘HIV rapid diagnostic tests’; 'HIV epidemic', 
'quality control of rapid test kits', 'sensitivity and specificity of rapid HIV test kits', 
'negative predictive value', positive predictive value', 'HIV prevalence' and 
'discordant HIV results'.  A manual review was also conducted, for example of 
conference abstracts that were relevant to the study topic.  
 
1.3 HIV and AIDS Burden 
1.3.1 Global 
HIV is still one of the world's most detrimental health and development challenges.  
An estimated 35.3 million people globally were living with HIV in 2012 (UNAIDS 
2013). In 2014, this number increased to 36.9 million (UNAIDS, 2015; UNAIDS 
2015b), mainly due to people receiving the life-saving antiretroviral therapy, more 
infections and general population growth. It was further reported that there were 
2.3 million new HIV infections globally, showing a 33% decline in the number of 
new infections from 3.4 million in 2001 (UNAIDS 2013). At the same time the 
number of AIDS deaths declined with 1.6 million AIDS deaths in 2012, down from 
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2.3 million in 2005 (UNAIDS, 2013). A further decrease in deaths was reported in 
2014 where 1.2 million people died (UNAIDS, 2015, UNAIDS, 2015b).  
1.3.2 Sub-Saharan Africa 
Sub-Saharan Africa, the most seriously hit region in the world by HIV, was 
reported to have 70% of people living with HIV in 2013, though it is only has about 
13% of the world’s population (UNAIDS, 2015; Population Reference Bureau. 
2014; UNAIDS Gap report 2014). Most children (88%) with HIV live in Sub Sahara 
(UNAIDS, 2015b). In the same year, there were an estimated 1.5 million new HIV 
infections and 1.1 million AIDS-related deaths (UNAIDS Gap report 2014). 
 
The region's epidemic is mostly generalized, meaning their national prevalence is 
greater than 1% (UNAIDS 2015). In 9 countries, 10% or more of adults are 
estimated to be HIV-positive. HIV prevalence in Western and Eastern Africa is 
reported to be low to moderate ranging from 0.5% in Senegal to 6% in Kenya 
(UNAIDS 2015). Swaziland has the highest prevalence rate in the world (27.7%). 
Recent data however shows that in many countries in the region, the national HIV 
prevalence and/or incidence is stabilizing or even declining (UNAIDS 2015).  
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1.3.3 South Africa 
The latest Human Sciences Research Council (HSRC) household-based survey 
2012, estimated that 6.4 million people were living with HIV in 2012 (Shisana O, 
2014) with a prevalence of 18.8% in adults as compared to 17% in 2008 (Shisana 
O, 2009). This makes South Africa the country with the largest number of persons 
living with HIV world-wide. The high prevalence is a result of new HIV infections 
and reduced mortality among individuals who are on ARV treatment (Bor J, 2013; 
Shisana O, 2014). In adults aged 15-49 years, the four HSRC surveys estimated 
HIV prevalence at 15.6% (2002), 16.2% (2005) and 16.9% 2008 and 18.8% in 
2012. The incidence for young people aged 15-24 was 1.49% with females at a 
higher 2.54% as compared to the male counterparts who had an incidence of 
0.55%. 
 
Data derived from population-based sero-surveys and sentinel surveillance of 
pregnant women suggest that the South African HIV epidemic has reached a 
plateau. The 2011 National Antenatal Sentinel HIV and Syphilis Prevalence 
Survey in South Africa reported an HIV prevalence of 29.5% in pregnant women 
(Health, 2012). In 2013, the ANC prevalence was estimated at 29.7 showing that 
the epidemic curve had plateaued and there has been no statistical difference in 
the national prevalence estimate in the past 10 years (Health 2013).The 
interpretation of prevalence is likely to become complex as the epidemic matures 
and prevention efforts try to mitigate it at the same time (Shisana O 2014). 
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1.4 The Response to HIV Epidemic 
1.4.1 Global 
In 2000, all nations agreed to global HIV targets with the goal of halting and 
reversing the spread of HIV by 2015, as part of the UN Millennium Development 
Goals (MDGs).The World Bank also launched its Multi-Country AIDS Program 
(MAP). The international community agreed upon new Sustainable Development 
Goals (SDGs), which include a target to end the AIDS epidemic by 2030 (United 
Nations 2015). The SDG related to Health is the SDG 3: Ensuring healthy life and 
promote well being for all at all ages (WHO 2014). 
1.4.2 South African Response 
In response to the HIV epidemic, the South African government reviewed the 
National Strategic plan (NSP) 2007-2011 (Health 2007) on HIV and sexually 
transmitted infections (STIs) and tuberculosis (TB) (Health, 2007) and developed 
the NSP (2012-16) (Health, 2012). The main objectives of the NSP (2012-2016) 
are to reduce the rate of new HIV infections by 50% by 2016 and to place 80% of 
patients who qualify for treatment on treatment by 2016 and retain them on 
treatment.  
 
The NSP has four strategic objectives aimed at comprehensively responding to 
the HIV epidemic as follows: Addressing the structural, social, economic and 
behavioural factors that drive the HIV and TB epidemics; preventing sexual and 
vertical transmission of HIV and STIs, and TB infections and disease, using a 
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combination of prevention approaches; providing universal access to affordable 
and good quality diagnosis, treatment and care; and ensuring that rights are not 
violated when interventions are implemented, and that discrimination on the basis 
of HIV and TB is reduced and ultimately eliminated.  
 
HCT expansion will play a crucial role towards achieving the NSP goals. 
Implementation of HCT in South Africa is guided by the national HCT Policy 
Guidelines that were revised and approved in 2010 (Health, 2010). The national 
policy guidelines support provision of HCT for everyone who is 12 years of age 
and above and further states that individuals require HCT for different reasons 
and/or circumstances including the following: individuals and couples who want to 
know their HIV status; pregnant women participating in the prevention of mother-
to-child transmission (PMTCT) programme; clinical diagnosis as part of basic 
patient care; research and other screening purposes; domestic violence and 
sexual assault; prior to providing post-exposure prophylaxis (PEP) after a needle 
stick injury, sexual assault and rape (acts of sexual penetration), per court order 
of the accused in sexual offence cases - Criminal Law (Sexual Offences & 
Related Matters Amendment Act No. 32 of 2007). 
 
On World AIDS Day 2014, UNAIDS set targets for 2020 aimed at ending the 
epidemic by 2030. The targets included achieving '90% of people living with HIV 
knowing their HIV status; 90% of people who know their HIV-positive status on 
treatment; and 90% of people on treatment with suppressed viral loads' (UNAIDS, 
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2014). WHO also revised the treatment guidelines and recommended the test and 
treat strategy for all those who test HIV positive (WHO, 2015). In order to align to 
the international standards, UNAIDS 909090 strategy and WHO guidelines as well 
as expand HIV testing, South Africa has embarked in the revision of the 2010 
policy guidelines to incorporate quality testing. The use of rapid HIV testing plays a 
crucial role with expansion of testing to enrol patients into care. While it is critical 
to expand HIV testing to meet these new goals, it is also very crucial that quality 
assurance implementation is improved.  
 
South Africa has made great strides in rolling out treatment as reflected by the 
number of patients in care from just under 1 million in 2010 to over 2 million in 
2012 (Shisana O, 2014). Despite these efforts, there is still a large proportion of 
individuals who have not been tested. 
 
1.5 HIV Prevention 
The South African government has embarked on the implementation of a 
combination of prevention programmes to interrupt HIV transmission. These 
interventions are segregated into three, namely, biomedical, socio-behavioural and 
structural factors. The main biomedical interventions implemented are HCT, 
condom distribution, MMC, STI management, youth HIV prevention, treatment, 
PMTCT, and high transmission areas (HTA) management. This process involves 
testing a large number of people using non-laboratory staff (Mashauri F, 2007). It 
is essential to ensure that QA procedures are followed from specimen collection, 
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testing and reporting of results in order to guarantee highly reliable and good 
quality HIV test results (Mashauri F, 2007). The programmatic interventions 
therefore required the implementation of high quality HCT as entry point. There is 
a need for simple HCT procedures especially in situations where HIV diagnosis is 
warranted, such as the PMTCT programmes (Cartoux M, 1998; Dabis F, 2002). 
 
An example of the need for HCT is PMTCT. Availability of ARV drugs to HIV-
infected pregnant women is crucial to prevent HIV transmission to their infants, 
extend prevention benefits to their HIV negative partners as well as to improve 
their own health. South Africa was one of the 22 priority countries participating in 
the Global Plan for elimination of new HIV infections among children by 2015. In 
order to achieve this goal, rapid HIV testing must be supported by scaling up QA 
measures.  
One of the goals of the NSP 2012-2016 is to reduce transmission of HIV from 
mother to child to less than 2% at six weeks after birth and less than 5% at 18 
months of age by 2016 (NSP, 2012-16). This included strengthening the 
management, leadership and co-ordination of the PMTCT programme and 
ensuring its integration with maternal and child health programmes.  
 
1.5.1 The Testing Gap 
With increasing availability of counselling and testing in many public health 
facilities in South Africa, uptake of counselling and testing is also increased. The 
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proportion of people who have ever had an HIV test and are aware of their status 
in South Africa has increased from 21% in 2002 to 50% in 2008 (Shisana O, 
2002;Pettifor A, 2004). Knowledge of HIV status in South Africa between the age 
groups, 15 years and older increased from 49% in 2008 to 66% in 2012 (Shisana 
O, 2014).  
 
In order to achieve the ambitious goals of the NSP, there is a need for an 
unprecedented effort to support health care facilities with delivery of reliable, high 
quality HIV diagnosis. The expansion of HIV counselling and testing (HCT) has 
implications for human resources (Taegtmeyer M, 2011), as it directly translates to 
expansion of not only services but also counsellors and testers. All the newly 
recruited personnel need to be trained on counselling, testing and quality 
assurance for testing to avoid compromising the quality of diagnosis while scaling 
up. In order to support the expanding implementation of quality testing, a need for 
task-shifting (a process where medical tasks are delegated to less specialised 
health care workers) has been identified and supported in response to the HIV 
epidemic (Samb B, 2007; Callaghan M, 2010). 
 
HCT in public health facilities is delivered mainly through rapid testing by non-
professional staff. The South African Minister of Health approved the provision of 
rapid HIV testing by non-professional staff in 2010 (Regulation gazette no. 9285 
Volume 539, 2010). This legislation repealed the Human tissue act that allowed 
only professionals to conduct rapid HIV testing. The gazette specifies that all non-
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professionals can provide HIV rapid testing provided they have been trained on 
the process. This supports the concept of task sharing between the professional 
nurses and the lay counsellors. Task sharing/shifting is an advantage in that it 
reduces the challenge of human resources for implementation of health care 
including HCT in public health facilities (Bedelu M, 2007;Chang LW, 2008; 
Sanjana P, 2009; Zachariah R, 2009; Callaghan, 2010). On the other hand, task 
shifting can also influence social dynamics in facilities (WHO, 2008; Tantchou and 
Gruénais, 2009). Other challenges for HCT include infrastructure where the public 
health facilities do not have enough rooms allocated for HCT (Tobi P, 2009) as 
well as requirement for training and supervision of lower cadres (Munga M, 2012).  
 
HCT is South Africa is also delivered through outreach activities including 
campaigns and in community testing and home based settings. These modalities 
are supported by the national HCT policy of 2010. In May 2010, South Africa 
launched the biggest HCT campaign in the world and by June 2012, more than 13 
million South Africans had tested for HIV (Mbengashe T, 2012). With the 
increasing demand for HIV testing as well as the fact that performing the test is not 
limited to health care professionals only, but includes lay counsellors and 
community care givers, the accuracy of HIV diagnosis using rapid test kits is 
crucial.  
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1.5.2 Statement of the Problem 
With the scale up of rapid tests (RT), and in response to the goals of the NSP, it is 
critical that QA is implemented and sustained to support accuracy of diagnosis in 
non laboratory services. Given the burden of infections in South Africa there were 
efforts to expand testing. It was recognised that QA of rapid testing was a key 
component to the implementation of testing. The South Africa QA programme is 
guided and supported by the national reference laboratory, the National institute 
for Communicable Diseases (NICD). The NICD has coordinated the 
implementation of QA by working with the provinces. The first phase was the 
adaptation of training material followed by an awareness training at a high level of 
provincial HIV, AIDS, STIs and TB (HAST) staff. The provinces were expected to 
provide rollout plans for QMS. With the change in legislation the QMS programme 
re-focussed on training a different cadre of staff and the training curriculum was 
revised. In addition, it was observed that the training cascade was not effectively 
reaching the facility level. A revised strategy was introduced to focus on the facility 
level training. The strategy included the use of an Internal Quality Control (IQC) 
programme. This approach was initially applied in Limpopo Province that had 
demonstrated QMS implementation based on site assessments. 
 
1.6 Addressing the Testing Gap 
1.6.1 HIV Rapid Diagnostic Tests (RDTs) 
HIV rapid diagnostic tests (RDTs) are single-use HIV assays that yield results in 
less than 30 minutes and do not have to be performed in the laboratory. Results of 
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RDTs are available quickly to enable individuals to learn their test result during the 
same site visit (Branson M, 2007). Early diagnosis provides an opportunity to 
access effective treatment earlier, with significant benefits for long-term survival 
and quality of life (Branson 2007). RDTs are also essential when immediate 
results are necessary to make decisions about treatment, for example, in 
pregnancy for PMTCT and in occupational exposure for PEP (Bulterys, 2004; 
Panlilio, 2005). In high-volume, high-prevalence settings, such as emergency 
departments, rapid tests can make testing more feasible and generate results 
quickly enough to influence clinical management (Lyss, 2007). 
 
While knowledge of sero-status through antibody testing is the current entry point 
for HIV prevention and treatment programmes (WHO, 2009), the currently 
available conventional laboratory based enzyme immunoassays (EIAs) require 
instrumentation (incubators, mechanical washing and optical reading devices), and 
expertise, are expensive and do not provide same day results (Yao K, 2010).  The 
introduction of rapid HIV tests has moved HIV diagnosis outside the traditional 
laboratory and integrated it into services such as point-of-care for ART, prevention 
of mother-to-child transmission (PMTCT) and HCT. Many studies have shown that 
with the scaling up of HCT world-wide, the introduction of rapid HIV assays is 
more appropriate than the traditional laboratory-based diagnosis as HIV rapid 
assays are more convenient for use in non-laboratory settings (Constantine N T 
2005, WHO 2005, Plate DK 2007, Moodley D 2008, Yao K 2010). 
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The use and availability of rapid HIV tests has made field diagnosis of HIV 
inexpensive as well as technically feasible in resource-limited settings (Wright R J 
2004). Rapid test processes are easy to perform, hence allow persons with 
minimal training and instruction to perform them (Ekwueme, D 2003). Results can 
be interpreted or read visually within a short space of time (Spielberg F, 1996, 
Giles R, 1999). Associations between incorrect HIV results given to patients and 
poor/no QA procedures at non-laboratory settings and their consequences have 
been shown in several studies (Gray J J, 1995; Gray RH, 2007; Azalao O, 2008, 
Bhattacharya R, 2008, Kagulire SC, 2011; Shanks L 2013, Shanks 2015)and the 
reasons this study seeks to establish the  effect of a QMS programme  on the 
accuracy of HIV rapid testing in HCT sites. 
The advantages of rapid testing include the fact it allows for an increased testing 
coverage and that it can be performed by non- laboratory personnel without the 
need of a formal laboratory training (Yao K, 2010; WHO, 2010; Peeling and 
Mabey, 2010).Rapid tests have been found to be cost-effective and to have 
increased the proportions of individuals receiving their HIV results (Global Fund, 
2009, Kates, 2009). 
 
Due to expanding need to provide access to affordable HIV monitoring services in 
general, a great deal of effort focused on the development of point-of-care 
technologies (POCT) (Setty MK, 2014). POCT diagnostics are in-vitro diagnostics 
(IVD) that do not involve the use of laboratory staff and facilities to provide the 
results (Setty MK, 2014); for example, RDTs. POCT enabled testing in many 
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settings without access to formal laboratory services that are located primarily in 
low- and middle-income settings and have dominated this diagnostics space. 
These technologies have revolutionized HIV diagnosis in developing countries 
(Schito ML, 2010). They are affordable, sensitive, specific, robust, easy-to-use and 
equipment free (Peeling and Mabey, 2010). The different test samples can be in 
the form of blood, urine, saliva, and/or other bodily fluids and (semi-) solids. These 
tests accept a sample with little or no preparation and provide a result, within a 
short period of time (Meagher RJ, 2008; Peeling and Mabey, 2010).  
 
Both RDTs and other POCTs have been at the core of many screening strategies, 
including voluntary testing and counselling, provider-initiated testing and 
counselling, home-based clinics, or community outreach–based testing and 
counselling. With the swift and widespread implementation of POCT globally, 
many barriers and impediments have been reported, which have prevented an 
ideal implementation (Reid SD, 2013; Johnson C, 2014). 
 
1.6.2 The Scale Up of RDTs 
The success of the public health approach to management of HIV lies in the large 
numbers of patients that have been tested and placed on treatment. There is no 
debate as to the success of the policy of using rapid HIV tests for HIV diagnosis to 
reach large numbers of people within a short time as shown by the high number of 
people in care (over 2.5 million in 2013) according to the NDOH annual report, 
(2014). The use of rapid HIV antibody tests in non-laboratory settings facilitates 
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access to care for patients. The South African HCT policy guidelines recommend 
that HIV rapid testing be prioritised in all non-laboratory settings and in 
communities to reach the populations that are at high risk of HIV acquisitions 
and/or transmission (Health, 2010). The national policy guidelines recommend the 
serial testing algorithm with the ELISA being utilised as the tie-breaker in 
discordant results (Health, 2010). 
1.6.3 Challenges of RDTs 
Despite the current successes, the use of rapid testing approach has many 
challenges if the protocols that govern its use are not rigorously followed. It is 
important that rapid test assays that are utilised in non-laboratory settings are of 
the same quality level when compared to that in laboratories. A combination of low 
levels of QA and inadequate staff training results in limitations to the effectiveness 
of non-laboratory-based rapid diagnostic testing programmes (Martin R 
2005,Chang D 2006, Perkins MD 2006). 
 
These challenges include monitoring the performance of the rapid test kits in terms 
of specificity, sensitivity, positive predictive value (PPV) and negative predictive 
value (NPV) as these may lead to unacceptably high rates of false positive and 
false negative results (Gray RH, 2007;Azala O, 2008;Kagulire SC, 2011).False-
positive results with HIV RDTs have been widely reported and attributed to a 
variety of causes including serological cross reactivity, test storage and transport 
conditions, poor quality control, lack of training and supervision of staff, limitations 
of the assay itself, sub-optimal national testing algorithms, workload, SOPs not 
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being followed, contaminating proteins in specimen and possible manufacturing 
defects (Gray RH, 2007; Shanks L, 2013, Shanks L, 2015; WHO, 2015; 
Klarkowsky, 2015). They usually lead to discordant test results, which delay 
diagnosis and, if the frequency of discordant results is high, undermine confidence 
in testing. However, if the tests used in the diagnostic algorithm are susceptible to 
the same cause for false positivity, then this may lead to a false-positive HIV 
diagnosis with potentially devastating consequences. False positive results, 
usually lead to people being placed on treatment unnecessarily, subjecting them to 
stress and wasting resources (Shanks L, 2013).  
 
In the case of false negative results, opportunities are missed, resulting in delayed 
treatment and continued infections (Shanks L, 2013). The implications of 
unreliable testing are deleterious and tragic. Reports indicate personal emotional 
distress, severe physical trauma from partners, abandonment and suicides, and 
some pregnant women have even been advised on and exposed to interventions 
to reduce mother-to-child transmission (Bhattacharya R, 2008;Shanks L, 2013). 
Appropriate monitoring for accurate HIV diagnosis will prevent misdiagnosis. Other 
reasons for misdiagnosing clients are associated with administrative errors, 
storage and transport conditions, poor quality assurance processes, lack of 
training and supervision of staff (Shanks L, 2013) . 
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1.6.4 HIV Treatment Cascade 
Antiretroviral therapy is considered successful when it suppresses the viral load of 
a person living with HIV to undetectable levels. Research shows that people who 
have an undetectable viral load, they need access to a continuum of services such 
as HIV testing and load in their blood are less likely to pass HIV to others (Cohen 
MS, 2011) and more likely to live a long and healthy life (Nakagawa F, 2012). For 
one to achieve an undetectable diagnosis, linkage to appropriate medical care 
(and other health services), support while in care, access to antiretroviral 
treatment if and when they are ready, and support while on treatment. This 
sequence of steps is commonly referred to as the HIV treatment cascade or the 
HIV care cascade. Unfortunately, the cascade isn’t seamless and some people 
“leak” out and are lost at each step, due to barriers to getting tested, staying in 
care, and starting or adhering to antiretroviral treatment. These barriers include 
poor access to services, stigma and discrimination, poverty, food insecurity and 
homelessness, and mental health and addiction issues (Hull MW, 2012). 
 As a result of these leaks at different points in the continuum, only a small 
proportion of people living with HIV are engaged in all the steps needed to 
achieve an undetectable viral load. For example, in South Africa, according to 
the national district health information system (DHIS) 2014, it was estimated that 
about 38% of people living on ART have an undetectable viral load, while 26% 
of patients not yet eligible
1.1). 
Figure 1.1. HIV treatment cascade for adults in South Africa including ANC, 
2014. (Source: Adapted from the Centers for Disease Control and Prevention 
– Morbidity and Mortality Weekly Report, December 2
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1.7 Different Strategies for HCT 
The traditional HCT strategy is client-initiated counselling and testing (CICT) 
(Alwayo-Edyegu, 1999). CICT as a strategy has become relatively standardised as 
HCT programmes grow in size, number and maturity. Evolving epidemic dynamics 
and increased funding for HIV control have led to expanded service provision and 
targeting of population groups not reached by existing strategies (Menzies N A, 
2009).  
 
New HCT strategies have been developed, that target different population groups 
and utilise different service delivery methods (HEAIDS, 2008). These strategies 
include provider-initiated counselling and testing (PICT), which is offered to all 
patients accessing the health services at the health facilities, and mobile HCT 
offered in communities and homes (WHO 2012). Currently, in South Africa, in 
addition to CICT, PICT is offered in all public health facilities in order to expand 
access to the HCT services. Furthermore, mobile HCT in communities is also 
implemented through district government mobile clinics and non-governmental 
organisations. The PICT strategy in public health facilities was adopted and 
approved in South Africa in 2010 and incorporated into the national HCT policy 
guidelines (Health, 2010). 
 
Since increasing the scale of HCT can raise knowledge of HIV status, HCT 
services should also be extended to previously underserved groups such as rural 
communities. Identifying HIV infected patients for treatment can be achieved by 
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expanding services to population groups in high prevalence areas. However, 
knowledge regarding how HCT may reduce HIV transmission is still debatable. 
Though two randomised control trials (Kamb M L 1998) have reported strong 
preventative effects, other studies (Matovu J K, 2005; Corbet E L, 2007; Sherr L, 
2007) have found little or no impact on risk behaviour or HIV incidence, particularly 
in HIV negative clients. Several meta-analyses studies (Higgins D L, 1991; 
Wolitski RJ, 1997; Weinhardt LS, 1999; Denison J A, 2008) have reported 
preventative effects to be strongest among HIV positive clients and discordant 
couples. A similar conclusion was reached by an additional meta-analysis 
conducted in developing countries by Denison J A, (2008). In the Democratic 
Republic of Congo, Zambia and Rwanda, cohort studies have been conducted 
following discordant couples (Kamenga M, 1991; Allen S, 1992; Allen S, 2003). 
These studies have consistently found strong beneficial effects of HCT on condom 
use and HIV incidence (Kamenga M, 1991; Allen S, 1992; Allen S, 2003).  
HIV testing is also essential for identification of HIV in pregnant women for 
prevention of mother-to-child-transmission of HIV (PMTCT), for protection of blood 
samples and to monitor disease trends in populations and clinical diagnostic 
purposes (Wright R 2004). Furthermore, HCT allows for proper monitoring of the 
HIV prevalence trends and the evaluation of the effectiveness of HIV prevention 
programmes (Wright R, 2004;WHO, 2005). Expanding the coverage of HCT can 
reduce HIV-associated stigma and discrimination as well as denial, hence mobilise 
communities to respond to the HIV epidemic (WHO, 2003). The use of rapid 
antibody tests has been endorsed by the WHO and have been adopted into 
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national guidelines in many countries in sub Saharan Africa including South Africa 
(WHO, 2004, WHO, 2015).  
 
1.8 Accuracy of HIV Diagnosis in Non-Laboratory Settings 
The monitoring of the quality of HIV diagnostic tests can have a significant impact 
on the accuracy of testing being provided to individuals. On the other hand, the 
lack thereof can compromise clinical management in that treatment may be 
wasted on patients that do not need it while patients who need treatment are 
delayed due to misdiagnosis (Peeling RW 2010). 
 
To ensure consistency, the rapid HIV assays that are utilised in non-laboratory 
settings must be of the same level of quality as that expected of laboratory testing 
whether performed by professionals or non professionals (Chang D 2006).A 
Quality Management System (QMS) can be implemented to varying degrees, but 
the basic principles still apply to any service providing HIV testing results. All sites 
conducting HIV testing should implement a QMS that incorporates the 12 
elements shown below in figure 1.2.  
The 12 elements adopted from the WHO HTS guidelines, 2015, comprise of the 
following: i. Organisation: all testing sites have a quality policy that specifies the 
crucial aspects of the testing. ii. Personnel: Any testing service must ensure that 
all personnel are adequately trained, certified and supported to implement the 
service. iii. Equipment: All essential equipment must be available and fully 
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functional. iv Purchasing and inventory: All sites must ensure that adequate 
supplies of test kits and other items required for the testing process are available 
at all times. v. Quality control: Testing sites must ensure that testing procedures 
are performed correctly and that the assay works as expected. vi. Information 
management: All sites must ensure that transcription errors are minimal. vii. 
Documents and records: All documents and records for all aspects of testing and 
its quality management system. viii. Occurrence management: All non 
conformances must be addressed and corrected. ix. Assessment: Both internal 
and external assessment must be undertaken to assure quality of testing. x. 
Process improvement: All areas that require improvement must plan and 
undertake improvements and evaluate their effect. xi. Client service: Customer 
and client satisfaction must be ensured. xii. Facilities and safety: It is key that 
testing sites are well designed and maintained. The testing site should be clean, 
and comfortable with adequate lighting and free of any potential hazards (WHO 
2015).      
 
  
Figure 1.2. Twelve Elements of a Quality Management System
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interpretation, therefore providing confidence in the testing process (Dax EM, 
1999; Chalker V J, 2005; Martin R, 2005; Chang D, 2006). Several factors can 
affect the accuracy of testing (Dax EM, 1999; Learmonth, KM 2008; Moodley, 
2008). While Spielberg F, (1989) demonstrated that the interpretation of assays for 
HIV detection read subjectively varied by 1.2-8.3% between readers, Learmonth 
KM, (2008) reported that both experienced and inexperienced readers in rapid 
testing interpreted the results with relative accuracy though they recommended 
that training and implementation of QA play a crucial role in accurate interpretation 
of rapid test results.  
 
This study focuses on an intervention for the process control namely the Internal 
Quality Control (IQC). There are two types of process control namely the in-built kit 
control and the independent internal quality control (IQC) that is used to check that 
an analytical phase or test precision is optimal (Gust, A 2001; Kettlehut M M, 
2003).The IQC are usually prepared independent of the kit manufacturer to avoid 
bias and is a well-characterised serological specimen. IQC confirms the quality of 
the test kit device before testing commences, on receipt of new batches/lots and in 
cases of extreme temperatures and prolonged storage. 
 
EQA, also referred to as proficiency testing (PT) is the tool used to assess the 
testing process independently. It is important to note that EQA can be used to 
identify training opportunities and not only to monitor technical performances 
(Chang D, 2006). Adequate initial and on-going training needs may be identified 
25 
 
by using carefully constructed EQA schemes. These are an important measure to 
ensure both proficiency and accuracy (Prevention, 2005;Prevention, 2007). The 
QA of rapid test kits must include on-site performance monitoring and the retesting 
of samples as well as EQA (Martin R, 2005). EQA is a vital component of QA and 
can be implemented in three approaches as follows: participation in external PT 
programs, supervisory site visits by external experts and retesting a subset of 
specimens in another competent laboratory.  
 
PT programs are normally effective as an EQA tool in recognizing poor performing 
sites (Parekh BS, 2010). Traditional PT programs and quality control reagents use 
serum/plasma specimens requiring stringent conditions for storage and 
transportation. To overcome the cold-chain transportation and PT panel delivery 
challenges, dried tube specimens (DTS) based PT are used as an alternative 
(Parekh BS, 2010).  
 
Briefly, small volumes (20µl/tube) of specimen are allowed to dry in tubes 
overnight. Once dried, DTS are stable at room temperature for at least a month 
and can be rehydrated at the testing site for proficiency testing purpose. The DTS 
is a dry pellet and, similar DBS specimens, has several advantages. It is stable, 
safer and less bio-hazardous than liquid specimens (Parekh BS, 2010; Benzaken 
AS, 2014). In addition, the specimens are stable at temperatures expected in 
many countries, especially during storage and transport and hence can be 
transported at room temperature without the need for maintaining an expensive 
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cold chain. Once received at the testing facility, the specimens can be stored at 
room temperature for few days without negatively affecting the integrity of the 
specimens. This general approach may also be extended in preparation of QC 
materials. Several countries are in the expansion phase of implementing DTS-
based PT programmes (Parekh BS, 2010).  
 
The lack of appropriate and on-going training of rapid HIV test implementers 
represents severe limitations to achieving quality diagnostic testing as it can lead 
to misdiagnosis (Delaney K P, 2002; Ziyambi Z, 2002; Granade T, 2004; Kanal K, 
2005). During the testing process mistakes could happen. These may include 
conducting testing outside of recommended temperatures, collecting specimens 
incorrectly, documentation errors, improper performance of testing, and incorrect 
interpretation of results (Greenwald J L, 2006). Adherence to QA procedures and 
ongoing test performance monitoring should reduce the number of testing 
mistakes that occur and increase the accuracy of results as reported by several 
studies (Delaney K P, 2002; Granade T, 2004; Wesolowski LG, 2006; Laura G 
Wesolowski, 2009; Wesolowsky L G, 2009). 
 
The ability of untrained rapid testing staff to conduct rapid testing has been 
documented (Granade T, 2004), hence it is recommended that all personnel 
implementing rapid testing be trained and supervised to improve accuracy of 
results. Trained laboratory personnel may also have challenges in performing, 
interpreting and communicating the results of rapid HIV tests if the initial training 
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was not adequate or efficacious (Kanal K, 2005; Martin R, 2005; Prevention, 
1998). Emphasis should be put on the importance of standardised on-going 
performance monitoring and training programmes which should be a requirement 
for all implementers (WHO, 2003). It has been reported that photographed rapid 
HIV test results may be useful as a cost effective training tool that could generate 
ongoing training interaction with the EQA processes (Learmonth KM, 2008). 
 
A study was conducted by Learmonth KM, (2008) to determine the feasibility of 
using difficult to read, photographed rapid HIV test results to assess the 
proficiency of operator interpretation and, secondly, the potential for using the 
method as a training tool. The study reported that photographed results of rapid 
HIV assays could be interpreted with comparative accuracy and that the prior 
experience of operators resulted in more accurate interpretation of photographed 
results. The results of their study showed that laboratory personnel who 
participated in the study, both experienced and inexperienced with rapid HIV 
assays were able to interpret the photographed rapid HIV results with relative 
accuracy. The authors further reported that the amount of experience acquired on 
the job also played an important role in achieving a greater accuracy of 
interpretation. Furthermore, the authors proposed that this method could be used 
in providing a novel, cost-effective EQA for non-laboratory rapid HIV testing. Once 
established, programmes could be used for training and monitoring purposes, 
facilitating the more accurate interpretation of rapid HIV assays and thereby 
assisting HIV prevention efforts, especially in resource limited countries. Most 
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importantly, photographed test results will bring a practical and cost effective 
approach to QA for the much-needed scale up of non-laboratory HIV testing 
(Learmonth KM, 2008). In South Africa, however, this method will be a challenge 
to implement considering the quantities of testing in South Africa (more than 10 
million tests per annum), where there is already lack of human resources (HR) to 
conduct the process, There will be a huge training need and training requirements 
and issues of timing for the process. 
In addition to PT, other EQA methods include re-testing or re-checking, and on-
site visits or evaluations as well as assessments including observations (Louis JF, 
2013). It has been reported that untrained implementers with no laboratory 
background are able to perform and interpret the results of a rapid HIV test 
accurately provided the methods are simple enough to be performed by this 
category of implementers (Galli A, 2013). In some developing countries, such as 
Cambodia, counsellors are exposed to half-day training on implementation of rapid 
HIV testing. A study was conducted to evaluate the proficiency of trained non-
laboratory health care personnel and laboratory technicians using the rapid test 
antibody technique. The accuracy of reports by counsellors was reported to be 
higher (100%) than that of laboratory technicians which supported the half day 
training that non-laboratory counsellors are usually exposed to before they can 
undertake HIV rapid testing in non-laboratory settings (Kanal K T, 2005).  
 
The performance of rapid RDTs has improved greatly with new assays developed 
based on new technologies; as a consequence, most rapid test assays have 
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comparable performance with ELISA assays (Branson M, 2000; Ketema F, 2001; 
Ferreira CJ, 2005;Peeling RW, 2006; Everett DB, 2009). RDTs may either be 
immune-chromatographic (lateral flow) or immune-filtration (flow through) with 
assays to detect HIV antibodies to HIV-1/2 infection and/or HIV-1 p24 antigen in 
finger prick capillary blood, oral fluids, serum, plasma and venous whole blood 
specimens (Pai NP, 2007; Pai NP, 2012). 
 
Serological RDTs for HIV-1/2 are categorised by generation characterised by 
antigen and/or conjugate used. The first three generations of HIV RDTs detect 
only antibodies to HIV-1/2 (WHO, 2012), thus individuals in the acute stage of 
infection, who may pose a substantial risk of HIV transmission to others may not 
be identified. The most recent generation of HIV RDTs (fourth generation) have 
been developed to detect HIV-1p 24 antigen, in addition to the HIV-1/2 antibodies 
tested for in previous generations of RDTs (Taegtmeyer M, 2011). Detection of the 
HIV-1 p24 antigen would allow earlier diagnosis of HIV when the infected 
individual is in the acute phase of infection and before development of antibodies 
to HIV-1/2. Fourth generation HIV RDTs are currently used in clinical practice in 
communities and clinical settings in both developed and developing countries 
(Taegtmeyer M, 2011). Fourth generation HIV RDTs are used as initial screening 
assays, followed by additional testing with two or three RDTs, depending on the 
underlying disease prevalence, to confirm the initial reactive test results. 
 
30 
 
A number of studies from different settings have been published showing the  
accuracy of the single available fourth  generation HIV RDT to be suboptimal for 
the HIV-1p24 antigen detection component, with low sensitivity for identification of 
individuals in the acute phase and other individuals with low p24 antigen titres 
(Chetty V, 2012; Rosenberg NE, and 2012; Conway DP, 2014). Fourth generation 
HIV RDTs are more expensive than previous third and second generation RDTs 
and the proclaimed additional advantage of their detection of acute infection could 
be misplaced (Chetty V, 2012; Rosenberg NE, 2012; Conway DP, 2014). 
Furthermore, it has been reported in several studies that sensitivities of RTDs may 
differ in acute infections (Cohen MS, 2010; Cook D, 2010; Patel P, 2012). 
 
1.9 HIV Testing Algorithms 
Algorithms are defined as the sequence in which assays are performed to detect 
HIV antibodies in a body fluid (WHO, 2003). HIV testing strategies have clear 
objectives for diagnosis, surveillance and transfusion safety. The need for 
appropriate selection of testing platforms and protocol had also varied from setting 
to setting. Sensitivity, specificity and prevalence of HIV infection in general 
population play an important role in the choice of appropriate tests for different 
settings (WHO, 2015). 
 
The decision to use parallel or serial testing algorithm is crucial and dependant on 
several factors including cost. In 2010, it was reported that if assays are properly 
selected, the positive predictive value (PPV) of 2 sequential reactive tests 
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(specificity ≥ 99%) is more than 90% even in low-prevalence populations (0.1%), 
and more than 99% in populations with a prevalence of 1% or higher (Parekh BS, 
2010). The author further reported that if the tests have a specificity of 98%, the 
PPV is more than 90% in populations with a prevalence of 0.5% or higher , 
(Parekh BS, 2010). 
 
One of the factors that may be used to determine the country’s algorithm is the 
performance of the tests used. The tests are based on how closely a rapid HIV 
antibody test agrees with the gold standard viz., ELISA. In South Africa, as in 
many countries, the gold standard is the ELISA and the recommended algorithm is 
the serial testing algorithm. The advantage of using an algorithm with rapid tests 
as compared to ELISA and Western Blot for confirmation, is its simplicity and 
rapidity (Ferreira CJ, 2005). These characteristics can be useful when addressing 
high- risk populations in which only one opportunity for counselling and providing 
results is possible. The adoption of an appropriate strategy could expand the 
availability of HIV counselling and testing, which may increase the number of 
individuals reached for encouraging the adoption of risk-reducing behaviour or link 
to care.   
 
Algorithms may consist of a screening test and a different confirmatory test to 
confirm initial positive results, or two tests in parallel with a third test as a tie-
breaker for discordant results. These testing strategies are referred to as serial 
and parallel algorithms, respectively (Richard J, 2
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one in which a single rapid test, if non-reactive, is not confirmed with a second test 
but recorded and reported as a negative result. If the first test is reactive however, 
it is confirmed with a second, different rapid test. Discordant results are resolved 
with the ELISA or a third RDT. The tie breaker approach is not supported by WHO, 
(WHO, 2011; WHO, 2015). Since HIV negative test results for the first or 
screening rapid test are not confirmed, the serial approach has the potential to 
miss some cases of HIV infection.  
 
In many sub-Saharan countries, several rapid testing algorithms that are utilised 
are usually based on the availability of test kits and not the proven specifications of 
an algorithm. Several studies in sub-Saharan Africa have demonstrated that 
commercially available HIV rapid test kits yield favourable sensitivities and 
specificities at site level, (Nunn A J, 1993; Koblavi-Dème S, 2001; Urasa W, 2002; 
Van den Berk GEL, 2003; Foglia G, 2004; Menard D, 2005; Kroidl I, 2012). The 
WHO recommended sensitivity is 99% for first and second line assays (RDTs) and 
100% EIA. While specificity is 98% for first line assays (RDTs and EIA) and 99% 
for second line assays (WHO, 2015). WHO does not recommend tie breakers for 
inconclusive results, but that clients be called back to re-test after 14 days as 
compared to the South African HCT guidelines (2010) that recommend ELISA as a 
tie breaker for inconclusive results and a sensitivity and specificity of 99% for first 
and second line assays (Health, 2010). Both quality and cost of rapid HIV 
diagnosis are critical in HIV rapid testing. It is, therefore, imperative to identify 
rapid testing algorithms that conserve finances by reducing the number of test kits 
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and support equipment used, while at the same time providing optimal 
performance (Wright R, 2004). With the expansion of HIV and AIDS treatment in 
Sub-Saharan Africa, knowledge of HIV status and choosing appropriate testing 
strategies remains critical.  
 
Understanding the functioning of rapid antibody tests in different testing algorithms 
is crucial to inform local and national testing HIV testing policies. Many sub- 
Saharan countries have implemented the serial testing algorithm. A well-informed 
choice of a testing strategy can lead to better results and significant cost reduction. 
Correct identification of HIV positive patients is the gateway to most HIV and AIDS 
prevention and treatment programmes and will be vital to any systematic effort to 
eliminate the epidemic. In order to reduce the number of incorrect results, it is 
recommended that individual tests are used in combination algorithms that 
perform better than single tests alone and that testing is conducted in a manner 
that is consistent with the manufacturer's instructions (Wesolowsky L G, 2009).  
 
The Food and Drug Administration (FDA) requires testing facilities that plan to 
perform rapid HIV testing to develop QA plans which include site specific testing 
procedures, plans for training (Mayhood MK, 2008), testing personnel and 
development of systems to identify and correct mistakes (Prevention, 2007). 
Adherence to QA procedures and ongoing test performance monitoring should 
reduce the number of testing mistakes and increase the accuracy of results 
(Wesolowsky L G, 2009). Despite the setting or the personnel who perform the 
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rapid HIV tests, the accuracy and reliability of diagnostics must be maintained for 
the success of HIV and AIDS programs.  
 
To ensure reliability and minimize errors, quality assurance measures must be in 
place to address all aspects of testing as rapid testing expands into non-traditional 
settings where testing is conducted by people without a laboratory background or 
formal health care training (Yao K, 2010). These include, IQC implementation, 
compliance to the recommended algorithm and SOPs and correct interpretation of 
results. Increased need for HIV testing has created an urgent need to train large 
numbers of personnel to meet the demand.  
 
There is a widely held assumption among healthcare workers that the rapid tests 
are as reliable and accurate in the field as in the laboratory, hence require little 
monitoring to ensure the quality of results. However, a review of eleven African 
countries with rapid testing programmes found that only seven had a system 
involving laboratory retesting, four conducted periodic on site observation, and two 
utilised proficiency testing panels (Plate, 2007). 
 
Monitoring the quality of test kits after procurement and before distribution is 
critical, i.e. post marketing surveillance (PMS). Any deviation in end-point 
sensitivity and/or specificity may indicate suboptimal performance of the assay. 
The quality of the test kit may be affected adversely by suboptimal transport, 
storage temperature, humidity, or other environmental factors (Parekh BS, 2010). 
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Additional measures are needed to determine the quality of kits after procurement. 
It is recommended that stored kits be validated at regular intervals or randomly 
picked from field sites for post marketing surveillance. IQC can also serve this 
purpose at test site level. Furthermore, appropriate policies need to be in place for 
a course of action in case compromised test kits are detected. 
 
1.10 Quality of Rapid Testing in the Field 
It has been documented that in the field, i.e. at counselling and testing sites, the 
specificity and sensitivity of rapid HIV test kits decreases as compared to the 
laboratory setting (Mayhood MK, 2008;Black V, 2009). This may be due to several 
factors such as storage conditions of test kits, handling, transportation, 
temperature, lack of training, lack of basic QA application, record keeping, and 
evaluation of test kits, testing algorithm and on-going monitoring and evaluation 
(Plate DK, 2007;Moodley D, 2008) reported that the sensitivity of four different 
rapid HIV test kits was 92.5-97.3% when administered under field conditions 
(antenatal sites) and 100% when performed in a laboratory by technologists using 
ELISA testing in Kwa-Zulu Natal, South Africa. They further reported that weak 
positive results could be difficult to correctly interpret and might lead to false 
negative diagnosis in the field. Low sensitivity of rapid test kits was also reported 
by in a clinic setting in Cape Town. They attributed this to poor adherence to 
testing policies by staff as per their observation (Wolpaw BJ, 2010).  
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Four RT kits were evaluated in Cameroon and it was found that the test 
sensitivities varied from 94.1% to 100% and the specificities varied from 88% to 
98.8%. The PPVs varied between 85.3 and 100% in a population with 11% HIV 
prevalence with the exclusion of discordant results as shown in table 1.1a. With 
the inclusion of discordant results the PPVs varied between 59.1 and 92.9% with a 
prevalence of 11% as shown in table 1.1b (Aghokeng FA, 2004).  
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Table 1.1a Results of evaluation of 4 rapid test kits in Cameroon without indeterminate results 
Test kit Sensitivity (%) Specificity (%) PPV: 11% 
prevalence 
NPV: 11% 
prevalence 
PPV: 7% 
prevalence 
NPV: 7% 
prevalence 
Genie II 
 
98.9 100 100 99.3 100 99.3 
Immuno 
Comb II 
99.3 99.5 98.1 99.6 97.5 99.6 
Determine 
HIV 1+2+0 
100 98.3 94.4 100 91.5 100 
Camstix-
HIV1+2 
100 98.3 94.4 100 91.5 100 
 
Table 1.1b Results of evaluation of 4 rapid test kits in Cameroon with indeterminate results 
Test kit Sensitivity (%) Specificity (%) PPV: 11% 
prevalence 
NPV: 11% 
prevalence 
PPV: 7% 
prevalence 
NPV: 7% 
prevalence 
Genie II 
 
98.9 98.2 92.9 99.3 88.9 99.4 
Immuno 
Comb II 
99.3 97.4 84.6 99.5 84.6 99.6 
Determine 
HIV 1+2+0 
100 90.6 72.4 100 62.5 100 
Camstix-
HIV1+2 
100 88.3 67.9 100 57.4 100 
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Although evaluations conducted in resource-constrained countries have 
demonstrated that rapid HIV tests perform well in research settings, their 
performance may differ when used on a wide-scale due to lack of trained staff, 
poor laboratory infrastructure and weak quality assurance programmes (Kline RL, 
1994; Andersson S, 1997; Stetler HC, 1997). 
. 
The performance of two rapid HIV test kits was tested and validated under field 
conditions in Northern Tanzania and it was reported that the sensitivities, 
specificities, PPV and NPV of the test kits were reduced from 100% to a range of 
98-99% (Mayhood MK, 2008). In addition, the diagnostic performance of two rapid 
tests for HIV-1/2 in plasma and in whole blood were evaluated, where lower 
sensitivities and specificities of the RDTs were reported in the field (Kroidl I 2012). 
These results support earlier studies (Gray J J, 1995; Ramalingam S, 2002;Van 
den Berk GEL, 2003; Ferreira CJ, 2005; Menard D, 2005; Plate DK, 2007). 
 
In order to address the QA issues, efforts have been invested by international 
organizations such as CDC, WHO, PEPFAR and at a National level. Examples 
include CDC/WHO network meetings and stemming from such meetings is the 
development of a QA curriculum that addresses HIV rapid testing specifically 
(WHO, 2004). This responds to the need for reliable diagnostic assays capable of 
ensuring the correct identification of infected individuals and the safety in blood 
transfusion (Aghokeng FA, 2004). The use of rapid point-of-care tests, introduction 
of services to prevent mother-to-child transmission, and increasing provision of 
39 
 
antiretroviral drugs were key events that facilitated the expansion of HIV 
counselling and testing services (Marum E, 2012). Innovations in service delivery 
included providing HIV testing in both clinical and community sites, including 
mobile and home testing (Marum, 2012). Promotional campaigns were conducted 
in many countries and evolutions in policies and guidance facilitated expansion 
and uptake (Marum E, 2012). 
 
The HIV diagnostic market has grown greatly producing a number of different 
rapid HIV test kits in the market. Not all test kits are manufactured under good 
manufacturing processes (GMP) standards. Some kits may be produced by the 
same manufacturers and sold under different names by several different 
companies. This means that occasionally the same test kit or its components are 
manufactured in multiple facilities; some of which may lack appropriate inspection 
or approval by regulatory agencies (Parekh BS, 2010). Several steps should be 
followed to assess the quality of test kits at various levels of the evaluation 
process (Figure 1.3). 
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Figure 1.3 Assessment of the quality of HIV rapid test kits: WHO, GMP: Good 
manufacturing processes (Parekh BS, 2010). 
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41 
 
Furthermore, to ensure that rapid tests perform as expected, WHO developed 
guidelines for country-based evaluation and implementation of rapid HIV testing 
(WHO, 2004). These guidelines recommend a three-phase approach (figure 1.3): 
In phase 1, candidate rapid HIV test kits are evaluated for sensitivity and 
specificity in a reference laboratory. Tests that demonstrate acceptable 
performance are then selected for phase 2, which is, the field evaluation. This 
assesses the performance of rapid test kits singly or in combination testing 
algorithms at point of care (POC) sites under the conditions of intended use. 
 
Depending on the evaluation results, a rapid HIV testing algorithm is developed 
using 2 or 3 rapid HIV tests that fulfil the selection and performance requirements 
(Chaillet P, 2009). Phase 3 recommends the implementation of the suitable 
algorithm with a system of continuous quality assurance that optimally includes 
training, supervision and competency assessment of personnel who perform the 
tests, site visits to observe testing and EQA based on re-testing a proportion of 
specimens by reference laboratories (figure 1.4). 
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Figure 1.4. In-country evaluation of rapid HIV tests Adapted from Guidelines 
for appropriate Evaluations of HIV testing technologies (WHO, 2003) (Plate 
DK, 2007). 
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Following the implementation of the pre-qualification programme, the United 
States Agency for International Development (USAID), in collaboration with U.S. 
CDC, instituted a vigorous test kits validation program to support and enable 
different implementing countries to have access to HIV rapid test kits that are not 
yet FDA approved but meet the performance criteria. This evaluation is performed 
using a well-characterized global panel of serum/plasma specimens obtained from 
several countries with diverse HIV-1 subtypes and HIV-2. Validation also includes 
a comparison of 3 kit lots to assess lot-to-lot consistency. Test kits are rated for 
different characteristics including provision of all testing components and devices 
used, recommended storage temperature, shelf life, training needs and ease of 
use and interpretation. 
 
The expectation from WHO was that each country would develop appropriate 
plans that would result in an implementation of QA at testing sites as well as 
monitor the effectiveness of the implementation. The guideline was developed to 
review aspects such as consensus on the training curriculum, followed by phases 
such as direction setting, alignment, readiness, implementation and monitoring 
and evaluation. South Africa developed the national HCT policy guideline and the 
national QA guidelines in 2010 to guide the implementation of HCT (Health, 2010). 
 
1.11 QA Strategies 
Several tools and models may be used to monitor and improve the quality of 
testing. These include algorithm choice, procurement and storage, training and 
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refresher training, reporting, supervision, observed practice, use of a logbook for 
data collection (Appendix 1) and implementation of an EQA programme as well as 
an internal quality control (IQC) programme. The use of a standardised logbook to 
monitor and improve the quality of testing on-site is important. Incomplete 
information, lacking test kit names, lot numbers and expiration dates makes it 
difficult to trouble-shoot problems (Parekh BS, 2010).  
 
The retesting strategy involves the collection of every 10th specimen as serum or 
dried blood spot (DBS) and sent to a reference laboratory for retesting to 
determine the extent of field site accuracy. While such strategies are important to 
improve the accuracy of rapid testing, some limitations in resource- limited settings 
may include the following: cost and the lack of trained personnel for 
implementation (Learmonth KM, 2008).  
 
1.12 QMS Implementation Strategies in South Africa 
Ideally, to implement a high quality strategy for QMS the following must be taken 
into consideration: direction setting to define goals, alignment to all relevant 
stakeholders, system readiness, implementation to scale and monitoring and 
evaluation (Yao K, 2010). South Africa has a national QA guideline that was 
developed in 2009 to guide provinces regarding implementation of quality 
assurance. The NDoH is currently implementing the following interventions: post-
marketing surveillance, both active (testing new lots) and passive (IQC and PT), 
by NICD (national reference laboratory) for all test kits on tender, standardised 
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training curriculum for QMS, training of trainers programme by the NICD 
throughout the country for implementation of QMS and development of standard 
operating procedures. The trainers are expected to disseminate the training to all 
end users in their facilities.  
 
Consultations have been conducted with provincial programme managers to make 
them aware of the expectations for QA implementation. The IQC programme 
piloted in Limpopo province is currently being rolled out to other provinces. This 
programme involves using known HIV positive samples and HIV negative samples 
to validate the test kits before use at the facilities. NICD provides both HIV 
negative and HIV positive controls for validating test kit device performance during 
the pilot study. All staff members who routinely offer HIV testing were trained 
through the TOT model prior to commencement of the pilot. The staff was 
monitored regularly and offered technical support. Based on the results, the 
intention is to expand the roll out the programme.  
 
In South Africa, a testing strategy using Dried Blood Spot (DBS) was implemented 
by a national HCT implementing partner, namely, New Start. This approach is, 
however, only statistically valid for sites with a high volume through-put, i.e. 5,000 
specimens or more per time period. It is not recommended to retest specimens for 
low volume sample through-put, as a much higher proportion (40% to 90%) of 
specimens will have to be retested in order to be able to detect significant error 
rates of 1-5% (WHO, 2004). Furthermore, the re-testing programme has certain 
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constraints including requirement of staff, time and lack of timely results to affect 
the outcomes. While South Africa supports the different QA strategies that New 
Start implements, re-testing may not be practical in public health settings due to 
the quantities tested on a monthly basis, lack of technical staff to implement and 
logistics. The country has opted to implement PT in addition to IQC and focus on 
training, mentoring and supervision of implementers. Countries such as Rwanda, 
Cameroon and Tanzania have implemented EQA (Granade T, 2004;Mashauri F, 
2007;Chaillet P, 2009). 
 
1.13 New Start: NGO QA Strategies 
New Start is an NGO that is funded by PEPFAR to complement the government 
HCT programme (www.newstart.co.za). It has implemented HCT in non medical 
sites in all 9 provinces since 2004. New Start is one of the biggest HCT 
implementing partners in the country and it has sites whose only role is to provide 
HCT services in the community. New start sites are called non-medical sites 
because they do not provide any primary health care to participants. New Start 
was selected for the study as it implemented several quality assurance measures 
at all sites for HIV testing therefore presented a good opportunity for comparison. 
These included, QA procedures covering the equivalent 12 elements applied to 
laboratory-based QA, IQC, EQA viz., proficiency testing panels (PT) and the re-
testing process. New Start sites employed a quality manager who was a laboratory 
technologist and training was provided on competency for HIV testing and quality 
assurance to all employees involved in the implementation of HIV rapid testing.   
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Furthermore, New Start sites also had monitoring and evaluation managers for 
HIV rapid test quality management, who monitored the progress of the programme 
and the implementers (counsellors and testers). New Start utilised the National 
Institute for Communicable Diseases (NICD) for quality assurance of rapid HIV 
testing, which included HIV ELISA testing as a confirmatory method for rapid HIV 
testing (retesting), IQC and PT panels (plasma). For retesting, 10% of specimens 
(DBS) were sent to NICD for validation.  
 
There is paucity of documented assessment of the implementation of QA at HIV 
rapid testing sites in South Africa, i.e. there is no systematic programme to monitor 
the implementation of the necessary trainings at facility level, as well as the 
implementation of quality assurance measures and guidelines in the country 
(SEAD, 2010; Moodley, 2008). The SEAD study aimed at analysis of VCT 
implementation in South African public health facilities. The study was an 
evaluation that identified potential problems observed during HCT service such as 
availability of test kits on tender, swabs, stop watches, wearing gloves, 
counselling, availability of registers and any form of QA, but did not quantify 
accuracy of testing, nor look into sensitivities, specificities, PPVs or NPVs.   
 
South Africa is currently implementing the following QA aspects: 
Test product validation: All rapid HIV test kits that are utilised in public health 
facilities in South Africa are subjected to a pre-qualification validation by the 
National reference laboratory, NICD. After selection and prior to implementation, 
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all test kits on the tender are subjected to a post-marketing surveillance process to 
validate the test kits against specific requirements set out such as sensitivity, 
specificity and stability (Parekh BS 2010). 
 
Training: A country-specific rapid testing quality management system (QMS) 
curriculum was adopted in 2006. Provincial training rollout plans were developed 
in 2007, followed by training of project management and master trainers since 
2008 by the National reference laboratory (NICD). Training is ongoing as required. 
New Start staff has undergone this training. 
 
Training strategy rollout plan: The rollout strategy has been developed. The 
strategy is followed by QMS training of key personnel (ToTs) including master 
trainers, programme managers, mentors and regional training centres (RTCs) by 
NICD. It is expected that training will be cascaded to district and facility level by 
each province. Developed provincial plans are followed by continuous monitoring 
of effectiveness of training. 
 
QA guidelines: In South Africa, QA guidelines were developed in 2009 (Health, 
2009). The QA guidelines were circulated in provinces through provincial 
coordinators. Provincial coordinators have been trained on implementation of the 
guidelines and are expected to cascade the training throughout the provinces. 
Provincial coordinators have been trained on the implementation. 
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IQC: The IQC pilot project was implemented by the Department of health and 
NICD in Capricorn district in Limpopo in 2010. The rollout of IQC in the Limpopo 
province has been completed. 
 
1.14 Study Aims and Objectives 
1.14.1 Aim 
To determine the accuracy of HIV rapid testing in two provinces in South Africa-
one in the presence and one in the absence of a Quality Assurance indicator 
(IQC). 
1.14.2 Objectives 
• To assess the sensitivity and specificity of rapid test kits in two provinces  
• To assess the sensitivity and specificity of rapid test kits between the two 
provinces and New Start NGO which implemented a more comprehensive 
QMS 
• To assess the accuracy of HIV rapid testing in the two provinces 
• To assess the accuracy of HIV rapid testing between the two provinces and 
New Start sites.  
1.15 Hypothesis  
The accuracy of HIV diagnosis using HIV rapid test kits in non-laboratory settings 
in which an intervention has been introduced (IQC) will not be different compared 
to settings that do not utilize IQC.  
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2 CHAPTER 2: METHODOLOGY 
2.1 Introduction 
This chapter describes the study background, design, setting, population, 
implementation and data management. Eligibility criteria for recruitment into the 
study are described in detail. The prospective and retrospective datasets used for 
the analysis are also described, including the measures taken to ensure credible 
data quality. The chapter ends with a review of the methods used for data 
processing and ethical considerations.  
 
2.1.1 Limpopo Pilot Project 
Between June 2009 and September 2010, the Department of Health and the NICD 
initiated an IQC pilot project in Limpopo in support of the rapid HIV testing 
programme. The pilot project was followed by full implementation of the use of  
IQC as part of a quality assurance initiative for HIV rapid testing. The pilot study 
was to determine the feasibility of the intervention and with the aim of full 
implementation after the pilot. The effectiveness of IQC on the quality of HIV rapid 
testing was not known. In this pilot project, IQC was implemented routinely in 23 
selected sites as part of QA measures in the Capricorn district.   
 
In South Africa, the current gold standard for diagnostic approach within the public 
sector as recommended by the National Health Laboratory Services (NHLS) 
Virology Expert Committee is a serial 2-test algorithm. The recommendation is that 
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in the case of a reactive test result the second confirmatory result should be 
different in terms of antigens and technology. The Expert Committee 
recommendation is that positive results should be confirmed with a second 
independent specimen in 14 days. In the case of HIV rapid testing the national 
policy similarly recommends a serial 2-test algorithm for diagnosis where a 
reactive screening test is confirmed by a different confirmatory test. If the 
confirmatory test is reactive the diagnosis is positive. If test 1 is non-reactive then 
the diagnosis is negative. In case of discrepant results an ELISA test is 
recommended as a tie-breaker (HIV Counselling and Testing (HCT) Policy 
Guidelines 2010). The above algorithm has replaced the use of the Western blot 
as a confirmatory test in South Africa. The rationale for the change was based on 
the sensitivity and specificity of 3rd and 4th generation ELISAs, workload, costs and 
expertise.  
 
2.2 Training 
In both Provinces all lay counsellors were routinely trained on the 10-day HIV 
counselling and testing and 2 day HIV rapid test competency training. A counsellor 
was deemed competent if there was successful demonstration of a rapid test 
performance and results interpretation during training.  
 
In Limpopo, in addition to the 10-day HCT and the rapid test competency training, 
the counsellor received the following training curriculum developed by the NICD 
and approved by the NDOH: training of trainers (ToTs) on QMS (3 days), HRT (2 
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days refresher), IQC (2 days) and PT (1 day). All nurses and counsellors who 
provided rapid HIV testing in facilities were trained in the three areas. SOPs were 
developed and all staff were oriented on the use of SOPs. Job aides were also 
developed for use by implementers. All ToTs were conducted by NICD and 
NDOH. All participants received competency certificates for each training. SFH 
had developed for its New Start franchises a detailed training programme as part 
of its QMS including RDT, IQC, and EQA, data management. Counsellors also 
had to go through competency training prior to start of testing. 
2.3 Implementation of HCT 
2.3.1 QC 
The IQC specimens were characterised by serology testing including two ELISAs, 
RTD and WB testing in the case of positive specimens and provided as HIV 
negative and HIV positive serum samples. SOPs for storage and use of IQC 
samples were provided with the samples and training on SOPs was conducted. 
Each counsellor used these QC samples first to confirm validity of the test kits 
prior to testing of patients. The IQC specimens were used at the beginning of each 
week and on receipt of new batches. The results were recorded in a logbook. The 
counsellors were closely monitored by the sister-in-charge to ensure compliance. 
In cases of IQC failure, root cause analysis was conducted and recorded in the 
log-books.  
 
 2.3.2 RDT in HCT services
Rapid HIV testing was performed by trained lay counsellors in both provinces and 
in New Start sites. New Start further used ELISA testing per a diagnostic 
algorithm. All counsellors implemented HCT following the serial testing algorithm 
as per South African HCT Policy (Health 2010) (Figure 2.1) where in case of 
discrepant results ELISA was used as a tiebreaker. 
 
Figure 2.1 National HIV rapid Testing algorithm Source: HCT Policy 
Guidelines: 2010, National Department of Health.
Screening Test 1
Screening Result 
Test 1: non-reactive
Report Result:
HIV Negative
Confirmatory Result 
Test 2: Non
Collect Blood for ELISA
ELISA Result: Reactive
Report Results: 
HIV-Positive
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Screening Result
Test 1:  reactive
Confirmation 
Test 2
-reactive
ELISA Result: Non-
reactive
Report Results: 
HIV-Negative
Confirmatory Result 
(Test 2):  Reactive
Report Result: HIV-
Positive
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HCT was offered in counselling rooms and delivered in the form of client-initiated 
counselling and testing (CICT) also known as voluntary counselling and testing 
(VCT). In this study, HCT was offered only by trained lay counsellors. There were 
3 counsellors per site on the study in Mpumalanga while Limpopo had 5 
counsellors per site implementing HCT. Attendees who presented for HCT at all 
the selected study facilities were introduced to the facility general health 
information session which included basic information on HIV and AIDS. The study 
was introduced to the attendees during this briefing session.  
 
The information session was followed by individual pre-test counselling sessions, 
where participants were given detailed study information to enable them make 
informed decisions regarding participation. Recruitment was made based on the 
study inclusion criteria as described. Informed consent forms were administered to 
participants who agreed to participate in the study. Thereafter, rapid HIV testing 
was performed on all study participants following the national algorithm (figure 
2.1). The national HIV rapid testing algorithm was a serial testing process, where 
screening was conducted using ABON™ HIV 1/2/O Tri-line HIV Rapid Test Device 
(Trinity Biotech Manufacturing Ltd, China). All non reactive results were recorded 
as HIV negative. All reactive screening results were confirmed with First 
Response® HIV 1-2.0 rapid test kit (Premier Medical Corporation, Ltd, India). If the 
confirmatory result was reactive then patients were reported as HIV positive. All 
discordant results were sent for ELISA as a tie breaker. The screening and 
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confirmation test kits were allocated through the national tender to both provinces 
where the study was conducted.  
 
All participants were informed of their rapid HIV test results, received post-test 
counselling and were referred appropriately for further management, based on 
their HIV test results as per standard national guidelines. All participants who 
tested HIV negative on rapid test were requested to come back for re -testing in 6 
weeks in cases of possible recent exposure per policy guidelines. All participants 
who tested HIV positive were managed appropriately according to the national 
guidelines (Health 2010). All ELISA testing results were sent back to the facility to 
be recorded. This provided an opportunity to call back patients in case of 
discrepant results. 
2.4 ELISA Assays 
All participants provided whole blood for ELISA testing irrespective of their rapid 
HIV test results. The ELISA testing algorithm used was a serial testing algorithm in 
both Limpopo and in Mpumalanga NHLS laboratories (figure 2.2). The screening 
was conducted with Cobas E411, Roche, Germany, while confirmatory was 
conducted with the Advia Centaur ® HIV 1/O/2, Enhanced (EHIV) Siemens, 
Germany. Both ELISA assays were 4th generation tests. All non reactive results 
with the screening tests were reported as HIV negative. All reactive results were 
confirmed and if confirmatory is reactive, the participant was reported as HIV 
positive. If the confirmatory results were non reactive, the patient were recorded as 
discordant.  
 Figure 2.2 NHLS HIV ELISA diagnostic testing algorithm
 
 
 
 
Non-Reactive: Report 
(HIV negative)
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Screen (ELISA: 
Cobas® E411)
Reactive 
Confirm (ELISA: Advia 
Centaur® HIV 10/2/)
Reactive: Report 
HIV Positive 
Non-Reactive 
(Report discordant) 
exclude 
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2.4.1 Basic Principles of the Assays 
i. Advia Centaur ® HIV 1/O/2, Enhanced (EHIV) Siemens, Germany.  
 
The Advia Centaur ® HIV 1/O/2 is an antigen sandwich immunoassay. It utilises a 
sandwich assay that includes a biotinylated monoclonal anti-p24 antibodies/HIV-
specific recombinant antigens/HIV-specific peptides, and monoclonal anti-p24 
antibodies/HIV-specific recombinant antigens/HIV-specific peptides. 
ii. Cobas® E411 Roche, Germany  
 
The Cobas® E411 utilises a sandwich assay that includes a biotinylated 
monoclonal anti-p24 antibodies/HIV-specific recombinant antigens/HIV-specific 
peptides, and monoclonal anti-p24 antibodies/HIV-specific recombinant 
antigens/HIV-specific peptides. 
 
2.5 Specimen Identification 
All rapid HIV test results were bar-coded and recorded in the facility HCT register. 
All blood samples sent to the laboratory had a bar-coded sticker on the specimen 
bottle as well as the laboratory request form in order to track and trace the 
laboratory results back to the rapid HIV test results. All the bar-coded stickers for 
the study were in triplicate: one sticker was placed in the HCT register, one on the 
specimen bottle and the last one on the laboratory request form. All results were 
filed securely at the facility. 
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2.6 Retesting: DBS Retesting EQA for Retrospective Data 
Participants tested at New Start facilities were also tested through CICT/VCT by 
lay counsellors. DBS re-testing was an EQA tool used by New Start sites. For 
every tenth rapid test performed a dried blood spot was collected at the New Start 
testing facilities and sent to the NICD for HIV ELISA testing. All reactive ELISAs 
were confirmed with a second and different ELISA (Screen: Genscreen HIV ½ v2, 
Bio Rad; Confirmatory, Vironostika HIV Uniform II Plus). Both ELISA tests were 
third generation tests. 
 
2.7 Study Design 
Rationale: The study set out to determine the comparison between two tests 
(exposure and outcome) at a given time so a cross sectional design was most 
suitable to respond to this study objectives even though it may have certain 
limitations. While there are other designs such as a cohort design that could have 
allowed for a comparison of results with and without exposure to QA interventions, 
this study is looking at direct comparison of results at a given time and does not 
provide for follow-up testing. A cohort design would therefore, not have been 
suitable. Furthermore, this study was also nested within the operational 
interventions of the HCT programme in the selected sites which would have made 
a cohort design more challenging. Limitations of different alternative designs such 
as a cluster randomized control trial (RCT) and a stepped wedge RCT, are noted 
and discussed in the limitations section.  
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The study undertaken was of a cross sectional design in nature to evaluate the 
accuracy of testing in Limpopo Province and compared the results to Mpumalanga 
Province that had not instituted any quality assurance initiatives. The study data 
collection was conducted between August 2012 and April 2013. In addition, 
retrospective data from Society of Family Health franchises called New Start were 
sourced from the NICD laboratory for analysis in order to compare the accuracy of 
testing in non-medical sites implementing QA activities to that of the two 
provinces.   
2.7.1 IQC Pilot in Limpopo 
The known control samples were tested before commencement of rapid HIV 
testing at all times to identify any possible quality challenges and confirm the 
accuracy of the test kits. The IQC data were recorded in logbooks and validated by 
the facility manager (appendix 1). Standard operating procedures (SOPs) for HIV 
rapid testing and for IQC implementation were developed and all the testing staff 
were trained on these documents. All IQC samples were stored appropriately in a 
freezer and temperature was monitored and recorded on temperature charts. The 
implementation of IQC in these facilities was closely monitored. Re-training was 
conducted where needed. Baseline data were collected, followed by 2 monitoring 
visits. The implementation was on-going for 2 years before this study was initiated. 
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2.8 Study Setting and Population 
The decision to choose two provinces was due to the fact that the study aimed to 
compare the accuracy and extent of misclassification of HIV rapid testing in two 
provinces to determine effectiveness of the (IQC) intervention in one compared to 
other where the intervention was not applied. The study also tried to avoid bias in 
the one province (Limpopo) as the intervention was not entirely blinded within the 
province. Mpumalanga on the other hand, did not have the intervention at all in all 
the facilities. New Start was used as a reference to compare with the provinces as 
it had fully developed and implemented mature QA systems for a longer duration 
with a better degree of accuracy and therefore a good basis for comparison for the 
study. New Start also utilised the same algorithm as the provinces and provides 
VCT which is conducted by counsellors. 
2.8.1 Limpopo 
From the 23 sites that were selected to implement IQC pilot project in Limpopo 
between June 2009 and September, 2010, convenience sampling was applied and 
six sites were selected to participate in the study. The sites were identified by the 
provincial health authorities and selected based on the HCT head count of ≥ 100 
per month. The 6 sites identified comprised of 3 clinics and 3 hospitals namely, 
Nobody clinic, Seshego clinic, Sebayeng clinic, Seshego Hospital, Zebediela 
Hospital and Lebowakgomo Hospital.  
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2.8.2 Mpumalanga 
There were 6 sites conveniently selected to participate in the study comprising 3 
clinics and 3 hospitals. These sites were selected to participate in the study by the 
provincial health authorities based on their monthly HCT head count of ≥100. The 
6 sites included Ka-Bokweni clinic, Elukwatini clinic, Beatty clinic, Themba 
Hospital, Embhuleni Hospital, and Witbank Hospital. All the sites in Mpumalanga 
did not participate in the IQC programme implementation.  
2.8.3 NGO Implementing Sites 
New Start was an NGO funded by PEPFAR to complement the government HCT 
programme. New Start had HCT sites in selected districts in the 9 provinces and 
was one of the biggest HCT implementing partners in the country with sites whose 
only role is to provide HCT services in the community. New Start sites were called 
non-medical sites because they did not provide any primary health care services 
to participants; they i.e. only supported the government with the provision of HCT.  
 
New Start was identified for the study as it implemented several HIV testing quality 
assurance measures in all sites. These included IQC and EQA namely, proficiency 
testing panels (PT) and DBS retesting of 10% of previously tested data. New Start 
sites employed a quality manager who was a laboratory technologist and training 
was provided on quality assurance and competency testing of all employees. New 
Start utilised the National Institute for Communicable Diseases (NICD) for quality 
assurance of rapid HIV testing, which included HIV ELISA testing as a 
confirmatory method for discordant rapid HIV test results, IQC and EQA. DBS re-
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tested data for all New Start sites collected in 2008 were included in the study for 
analysis.  
 
2.9 Sampling Strategy 
2.9.1 Sample Size Calculation for Prospective Data 
For the prospective data, the sample size was calculated using Open Epi 
programme (Open Source Epidemiological Statistics for Public health) Version 
2.3.1. The following were the assumptions for the sample size calculation:  
National HIV Prevalence was estimated at 18.8% (Shisana O 2014). Confidence 
limit: 99.9%; P<0.05. The sample size calculated was N = 717. At the time of the 
study design, there was no data to use that was based on assessing accuracy of 
testing or misclassification, hence national prevalence was used for the calculation 
as a proxy measure. 
There was some objectivity in the calculation of the sample size and the study was 
focussed on achieving the required sample size. The sample size for the study 
was calculated to be 717. Divided equally across the study sites, this gives an 
average of 60 participants per site. However, the study was oversampled to take 
into account poor specimens, loss of specimens and administrative challenges. 
2.10 Sample Size Calculation for Retrospective Data 
Retrospective data, consisting of results of re-testing of 4825 samples (10% of 
total samples) collected in 2008 from all New Start sites were utilised for analyses. 
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While New Start was available in all 9 provinces, the available data for analyses 
was from 7 provinces and data from Mpumalanga was not available. The data was 
compared to ELISA to determine the degree of discordance.The rationale for 
analysing all available New Start data was to determine the accuracy of testing in 
systems that have matured QMS systems. 
 
2.11 Inclusion Criteria 
2.11.1 Participants 
o Both male and female attendees, 18-64 years of age 
o Must be at the clinic for HIV counselling and testing 
o Must be willing to sign an informed consent form for the study 
o Must be willing to provide blood for ELISA testing irrespective of the RDT results 
2.12 Data 
o The results for rapid HIV test kits and those for ELISA must be available 
2.13 Sites 
2.13.1 Limpopo 
o IQC implementation 
o Head count of ≥100 patients per month for HCT 
2.13.2 Mpumalanga 
o No IQC implementation 
o Head count of ≥100 patients per month for HCT 
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2.13.3 New Start 
o IQC and retesting methods implemented 
2.14 Exclusion Criteria for Study Participants 
2.14.1 Participants 
o Attendees under 18 years of age and over 64 years of age 
o Attendees who were not willing to provide whole blood samples for ELISA testing 
 
2.15 Data 
2.16 Data Cleaning and Quality Checks 
For prospective data, all participants’ HIV test results were bar-coded and 
recorded in the facility HCT register by the counsellor. Data were then extracted 
from the HCT register and entered into a pre-designed Excel spreadsheet. 
Variables extracted included age, gender and rapid test results. Retrospective 
data from selected New Start facilities were accessed from the NICD HIV results 
database. Data were tabulated to check for consistency and completeness. 
Missing variables were corrected by confirming with source documents (e.g. clinic 
HCT register). All errors and inconsistencies that were identified in this process 
were rectified.  
 
2.17 Statistical Analysis 
The Sensitivity (true positive rate), Specificity (true negative rate), Positive 
predictive value (PPV) and Negative predictive value (NPV) were determined for 
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the two provinces and New Start sites (Table 3.8). Calculations were conducted as 
per table 2.1. 
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Table 2.1 Calculations for sensitivity, specificity, NPV and PPV 
IV RAPID 
TEST ELISA TOTAL 
 HIV Positive  HIV Negative   
Positive A B A+B 
Negative 
 
C D C+D 
Total  A+C B+D  
 
• Sensitivity = A ÷ (A+C) 
• Specificity = D ÷ (B+D) 
• Positive Predictive Value = A ÷ (A+B) 
• Negative Predictive Value = D ÷ (C+D) 
• A = true positives; when the test under evaluation yield a positive result and 
the "gold standard" (the reference test method used to compare all other 
test results) yielded a positive result as well. 
• C = false negatives; when the test under evaluation yielded a negative 
result, while the “gold standard” or true value was positive. 
• A+C = all people who are truly infected with HIV 
• B = false positives; when the test under evaluation yields a positive result, 
while the “gold standard” or true value was negative 
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• D = true negatives; when the test under evaluation yields a negative result 
and the “gold standard” or true value yielded a negative result 
• B+D = all people who are truly un-infected with HIV Calculating Sensitivity, 
Specificity, PPV and NPV. 
 
To achieve objectives 3 and 4: To assess the accuracy of testing between the two 
provinces and New Start sites: 
Logistic regression models were constructed to estimate the Odds Ratios (OR) 
crude and adjusted) and these were used as a measure of association between 
exposure and outcome. Statistical significance was ascertained at 95% CI and a p 
value <0.05 was considered evidence against the null hypothesis. The sensitivity, 
specificity, PPV and NPV for the RDT and their 95% CI were calculated. All data 
analyses were conducted in STATA release 12 (Stata Corp., College Station, 
Texas, US).  
 
2.17.1 Descriptive statistics 
Data were analysed and presented as frequency distribution of characteristics. 
Frequency distribution was described for the following variables: test results 
(positive, negative and discordant). Age was analysed as a continuous variable 
and presented as frequency polygons. 
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2.17.2 Bivariate Analysis 
Bivariate analysis was done to identify association between factors using 
Pearson’s Chi square test for categorical variables. A p value of <0.05 was 
considered significant.  
 
2.17.3 Multivariate Analysis 
Logistic regression models were constructed to assess the association between 
the interventions in the provinces. Odds ratios were used as a measure of 
association between exposure and outcome and a 95% precision of estimate was 
used to ascertain statistical significance. Exposure factors with p<0.05 were 
considered statistically significant.  
 
2.18 Validity and Reliability of the HIV test kits 
Sensitivity, specificity, PPV and NPV were used to determine the reliability and 
validity of the rapid test kits (Table 3.8). The sensitivity and specificity values for 
Limpopo, Mpumalanga and New Start sites were further used with the national 
prevalence of 18.8% (Shisana O 2014) to determine the PPV and NPV at national 
level based on the following formulas from Baye's theorem (Okeh and Ugwu, 
2008):  
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And  
 
National Prevalence estimated at 18.8% (Shisana O 2014). 
2.19 Ethics approval 
Letters of support and permission to conduct the study were received from the 
provincial Heads of Department (HOD) for both provinces (Appendix 5 and 6). 
Meetings were convened with both provinces to introduce the study in the two 
provinces at district and facility levels.  
 
For analyses, only records from facility registers and laboratory forms were used. 
These were coded and kept in a locked cupboard at all times for the duration of 
the study.   
 
Informed consent for participation was obtained after a verbal explanation of the 
study to each participant during pre-test counselling sessions (Appendix 3 and 4). 
Participants were offered a copy of the signed informed consent form. It was 
explained to the participants that the purpose of the study was to compare the 
results of HIV rapid testing in clinical and hospital facilities to those of laboratory 
based ELISA method in order to improve HIV diagnosis methods in the facilities. 
All HIV negative participants were requested to re visit the facility after at least 6 
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weeks after testing to close the window period. All ELISA testing results were sent 
back to the facility to be recorded. This provided an opportunity to call back 
patients in case of discrepant results and in case they do not come back to the 
facility for re testing. Ethical approval was obtained from the Human research 
(Medical) Ethics committee of the University of the Witwatersrand. Permission 
from relevant provinces and facilities was obtained prior to implementation of the 
study (clearance certificate number: M111141) (Appendix 2).  
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3 CHAPTER 3: RESULTS 
3.1 Introduction 
This chapter provides results that respond to the objectives of the study. The 
overall study characteristics of the prospective data are given as well as the 
2009/10 piloted RDT IQC programme in Limpopo that was evaluated to determine 
whether it improves accuracy of RDT. In this chapter, the evaluation of accuracy of 
RDT kits versus ELISA in the two provinces, Limpopo and Mpumalanga is also 
presented. The results are compared to New Start sites. 
 
3.2 Pilot study for IQC Implementation in Limpopo 
Prior to the implementation of this study, an IQC pilot was conducted in LP as a 
PEPFAR supported intervention for rapid HIV testing programme in selected sites. 
On completion of the pilot, the study was conducted based on the results of the 
pilot. 
For IQC implementation, known HIV negative and HIV positive control blood 
samples sourced from NICD were utilised daily for the first three months and then 
the process was changed to weekly testing for the rest of the study. The frequency 
of IQC was first daily to ensure that the implementers are familiar with the process 
and once that was established, in three months, the frequency was changed to 
weekly and every time a new batch was opened.  
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There were no discrepant results between expected and recorded results during 
the pilot. The frequency of IQC was varied to ensure correct implementation in the 
initial period as this was a new technique and very close monitoring was need. 
After three months the frequency of use of the IQC was changed to once weekly 
as it was found that the counsellors had adapted sufficiently well to the routine use 
and recording of IQC results. IQC were also used on receipt of a new batch of RT 
for the remaining period of the study as part of regular QA processes for rapid HIV 
testing. 
The Limpopo IQC pilot study evaluated the feasibility of implementing IQC in HCT 
sites. The objectives of the pilot study were to establish: simplicity - ease of 
operation & adaptability, acceptability - staff willingness to institute IQC, logistics - 
storage and distribution and quality data management. Monitoring visits were 
conducted with an assessment tool to determine compliance to IQC 
implementation. Compliance was measured at three levels: full compliance which 
was measured as 80% compliance to standard requirements, partial compliance, 
measured as 50% of compliance to standard requirements and non-compliance, 
which was measured as less than 50% compliance to standard requirements. 
Figure 3.1below shows the number of IQC tests performed against the targets. 
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Figure 3.1. IQC implementation during the pilot project: Expected vs actual 
IQC performed 
 
Some implementers were not implementing IQC as expected and this was also 
rectified by additional training, support visits and mentoring. Standard 
requirements were defined as training of site personnel, staff participation at the 
site, SOPs and QA guidelines availability and use at the sites, control samples 
storage/integrity maintenance, data completeness, testing of both test kits in the 
algorithm, usage of both negative and positive controls, adherence to established 
frequency of IQC and continuity. Baseline data were collected, followed by 2 
monitoring visits. The results of the monitoring visits are shown in figure 3.2 below: 
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Figure 3.2. IQC pilot Project: Criteria for compliance 
 
Only training and sample integrity were above 80%which was deemed full 
compliance. Data management and completeness was lower than 50% and 
deemed non-compliant. The other elements were partially compliant e.g. there 
were differences in the number of IQCs performed for the screening test than for 
the confirmatory test. More training and mentoring were conducted to ensure full 
compliance on all elements before implementation and the results were full 
compliance. 
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3.3 Recruitment of study participants 
3.3.1 Enrolment Criteria 
A total of 947 participants who attended HCT in the selected facilities in 
Mpumalanga and Limpopo between August and April 2012, were screened to 
participate in the study. Out of the 947 participants who attended HCT in the 
facilities, 51 were excluded due to the fact they were outside of the age inclusion 
criteria. Of the 896 participants enrolled, 78 were excluded as HIV test results 
were incomplete; they were missing either the rapid test results or the ELISA 
results. The results of 818 participants remaining in the study were analysed. (See 
figure 3.3 below). Out of the 78 participants excluded due to unavailability of HIV 
results, 54 were from Mpumalanga while 26 were from Limpopo.
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Figure 3.3 Inclusion and exclusion criteria for study participants  
Exclusion criteria were as follows: 54 participants were excluded due to falling 
outside age inclusion while 78 participants were excluded due to the fact that they 
did not have both the HIV test results. The provincial distribution for exclusion was 
as follows: 
 
947 participants testing for RDT in 
Mpumalanga and Limpopo study sites 
818 participants included in 
the study for analysis 
896 participants 
51 Excluded: age >64 or 
<18years 
78 Excluded: No Elisa/RDT 
results 
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Table 3.1. Exclusion criteria for all participants 
 
 
3.4 Demographic data for Limpopo and Mpumalanga 
Out of a total of 818 participants, 457 (55.9%) participants were from Limpopo and 
361 (44.1%) from Mpumalanga sites (table 3.2). The data were significantly 
different, p = 0.021, (CI: 0.02-0.022). Of the 457 participants from Limpopo 
province, 102 (22.3%) were males and of the 361 participants from Mpumalanga 
province, 131 (42%) were males, p= 0.026. The mean age was 32.7 years (S.D 
±9.8) in Limpopo and 35.9 years (SD ±10.2) in Mpumalanga. The majority of the 
participants in both Limpopo (n=154, 33.4%) and Mpumalanga (n=122, 39.1%) 
were in the 25-35 years age group.  
 
In terms of age categories, the data from the two provinces were not significantly 
different, p=0.095. Gender and HIV status of participants, however, were 
significantly different, p=0.026 and 0.031 respectively between the 2 provinces. 
The rate of discordant HIV test results were significantly different in the provinces, 
p = 0.010. The HIV positivity rate between the two provinces was significantly 
different at 22.9% versus 26.0 % in Limpopo and Mpumalanga respectively (p 
value 0.012). In Limpopo the age of 26 (5.6 %) of participants was not known and 
Province Age exclusion No RDT/ELISA 
results 
Limpopo 19 26 (9 RDT, 
17ELISA) 
Mpumalanga 32 52 (15 RDT, 37 
ELISA) 
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in Mpumalanga 49 (12.7%) were of unknown age. Missing data on age were 
restricted only on age analysis and not on other variables such as RDT and ELISA 
test if results for the participants were available.  
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Table3.2 Characteristics of study participants 
 
Variable Limpopo: 
N (%) 
Mpumalanga: 
N (%) 
p-value 
Gender 
Male 
Female 
 
102 (22.3) 
355 (77.7) 
 
131 (42) 
181 (58) 
 
0.026 
 
Age Category  
(years)18-25 
26-35 
36-45 
46-64 
Unknown 
 
 
144 (31.5) 
154 (33.7) 
83 (18.2) 
50 (11.0) 
26 (5.6) 
 
 
81 (26.0) 
122 (39.1) 
62 (19.9) 
47 (15.0) 
49 (13.6) 
 
 
0.095 
HIV Status 
True HIV Positive 
True HIV Negative 
Discordant 
 
105 (23.0) 
325 (71.1) 
27 (5.9) 
 
94 (26.1) 
227 (62.8) 
40 (11.1)  
 
0.031 
 
0.010 
HIV positivity rate  105 (22.9) 94 (26.0) 0.012 
Totals  457 (55.9) 361 (44.1) 0.021 
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The clinics in Limpopo enrolled most of the participants as compared to hospitals, 
with Nobody clinic having enrolled 127 (27.8%) and Seshego and Zebediela 
hospitals having enrolled 33 (7.2%) each (table 3.3). Clinics enrolled more HCT 
clients than hospitals due to the fact that clinics were the first point of entry for 
health care including HCT. The patients diagnosed for HIV in hospitals were likely 
to be chronically ill with poorer outcomes.
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Table 3.3 Age, gender, HIV status and HIV status participants in Limpopo sites 
 
 
Variable 
Limpopo 
Province 
N (%) 
Zebediela hospital 
N (%) 
Lebowakgomo 
hospital 
N (%) 
Seshego 
Hospital 
N (%) 
Sebayeng 
Clinic 
N (%) 
Seshego 
clinic 
N (%) 
Nobody 
clinic 
N (%) 
Gender 
Male 
Female 
 
102 (22.3) 
355 (77.7) 
 
11 (33.3) 
22 (66.7) 
 
36 (46.2) 
42 (53.9) 
 
18 (54.6) 
15 (45.4) 
 
13 (11.6) 
99 (88.4) 
 
11 (14.9) 
63 (85.1) 
 
13 (10.2) 
114 (89.8) 
Age (yrs) 
18-25 
25-35 
35-45 
45-64 
Unknown 
 
 
144 (31.5) 
154 (33.7) 
83 (18.2) 
50 (11.0) 
26 (5.6) 
 
 
5 (15.2) 
13 (39.4) 
11 (33.3) 
4 (12.1) 
 
 
16 (20.5) 
22 (28.2) 
16 (20.5) 
24 (30.8) 
 
12 (36.4) 
6 (18.2) 
9 (27.3) 
6 (18.2) 
 
 
42 (37.5) 
37 (33.0) 
26 (23.2) 
6 (5.4) 
1 (0.9) 
 
36 (48.7) 
30 (40.5) 
4 (5.4) 
4 (5.4) 
 
 
33 (32.4) 
46 (45.1) 
17 (16.7) 
6 (5.9) 
25 (19.7) 
HIV Status 
Positive 
Negative 
Discordant 
 
105 (22.9) 
325 (71.1) 
27 (5.9) 
 
8 (24.2) 
22 (66.7) 
3 (9.1)  
 
24  (30.8) 
50 (64.1) 
4 (5.1) 
 
17 (51.5) 
12 (36.4) 
4 (12.1) 
 
26 (23.2) 
82 (73.2) 
4 (3.6) 
 
14 (18.9) 
54 (73.0) 
6 (8.1) 
 
16 (12.6) 
105 (82.7) 
6 (5.7) 
HIV Positivity   105 (22.9) 
 
8 (24.2) 
 
24 (30.8) 
 
17 (12) 
 
26 (23) 
 
14 (19) 
 
16 (12.6) 
Totals 457 (100) 33 (7.2) 78 (17.1) 33 (7.2) 112 (24.5) 74 (16.2) 127 (27.8) 
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Some of the clinics in Mpumalanga did not enrol more participants as compared to 
hospitals and this could be due to the excluded data for analysis where there were 
missing results (table 3.4). 
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Table 3.4 Age, gender, HIV status and HIV status participants in Mpumalanga sites 
 Mpumalanga 
Province 
N (%) 
Witbank 
hospital  
N (%) 
Embhuleni 
hospital 
 N (%) 
Themba 
Hospital 
N (%) 
Beatty  
Clinic 
N (%) 
Elukwatini 
clinic 
N (%) 
Kabokweni 
clinic 
N (%) 
Gender 
Male 
Female 
 
131 (42.0) 
181 (58.0) 
 
33 (67.4) 
16 (32.7) 
 
27 (69.2) 
12 (30.8) 
 
23 (48.9) 
24 (51.1) 
 
22 (24.4) 
68 (75.6) 
 
- 
- 
 
26 (29.9) 
61 (70.1) 
Age  (yrs) 
18-25 
25-35 
35-45 
45-64 
Unknown 
81 (26) 
122 (39.1) 
62 (19.9) 
47 (15) 
- 
12 (24.0) 
24 (49.0) 
10 (20.4) 
3 (6.1) 
- 
8 (20.5) 
9 (23.1) 
8 (20.5) 
14 (35.9) 
- 
9 (19.2) 
15 (31.9) 
13 (27.7) 
10 (21.3) 
- 
25 (27.8) 
37 (41.1) 
17 (18.9) 
11 (12.2) 
- 
- 
- 
- 
- 
49 (100) 
 
27 (31.1) 
37 (42.5) 
14 (16.1) 
9 (10.3) 
- 
HIV Status 
True Positive 
True Negative 
Discordant 
 
94 (26) 
227 (62.8) 
40 (11.1) 
 
15 (30.6) 
30 (61.2) 
4 (8.2) 
 
9 (23.1) 
26 (66.6) 
4 (10.3) 
 
10 (21.3) 
32 (68.1) 
5 (10.6) 
 
25 (27.8) 
57 (63.3) 
8 (8.9) 
 
12 (24.48) 
31 (63.26) 
6 (12.24) 
 
23 (26) 
51 (58) 
13 (14.9) 
HIV Positivity 94 (26.0) 15 (30.6) 9 (23,1) 10 (21.3) 25 (27.8) 12 (24.48) 23 (26.4) 
Totals 361 (100) 49 (13.6) 39 (10.8) 47 (13.0) 90 (24.9) 49 (13.6) 87 (24.0) 
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3.5 HIV rapid testing in Limpopo and Mpumalanga sites 
Data for HIV rapid and ELISA test results for Limpopo and Mpumalanga sites were 
compared to determine the difference between the rate of discordant HIV test 
results between the 2 provinces (Table 3.2). Discordant results were defined as 
those that were different between HIV rapid test and the ELISA test. The rate of 
discordant HIV test results in Mpumalanga was significantly higher than in 
Limpopo (Table 3.2). There was a range of discrepancy in the rate of discordant 
results within the facilities in both provinces though the numbers per site were 
relatively small (Tables 3.3 and 3.4). 
 
3.6 Accuracy of HIV RDT 
The sensitivity, specificity, PPV and NPV are presented in table 3.8.   
Table 3.5: Two by two Profile of HIV status for participants in Limpopo sites 
     
  Positive Negative  
 
RDT RESULTS 
Positive 105 0  
 Negative 27 325  
    457 
ELISA RESULTS 
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The number of true HIV positive results in Limpopo was 132 while that of true HIV 
negative results was 325 (table 3.5).   
Table 3.6: Two by two Profile of HIV status for participants in Mpumalanga 
sites  
 
  ELISA RESULTS 
  Positive Negative  
RDT RESULTS Positive 94 0  
 Negative 40 227  
    361 
 
The number of true HIV positive results in Mpumalanga was 134 while the total 
number of true HIV negative results was 227 (table 3.6).   
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Table 3.7: Two by two Profile of HIV status for participants in New Start sites  
 
ELISA RESULTS 
  Positive Negative  
RDT RESULTS Positive 537     14                                                                                                                           
 Negative 54 4220  
    4825 
 
The number of true negatives in New Start was 4234 and the true positive results 
were 591 (table 3.7). New Start data for HIV positivity and discordant rate is shown 
in table 3.8 where 1.4% results were discordant and the positivity rate was 11%. 
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Table 3.8: Data from New Start sites 
  
SITE  NEG POS TOTAL TESTED 
Discordant Concordant % Discordant 
CAPE TOWN 689 36 725 12 713 1.66 
DURBAN KZN 474 93 567 12 555 2.12 
GAUTENG JHB 662 92 754 1 753 0.13 
FREESTATE BLOEM 645 76 721 2 719 0.28 
MIDDLEDRIFT 280 16 296 1 295 0.34 
EAST LONDON 442 54 496 12 484 2.42 
PIETERMARITZBURG 192 40 232 3 229 1.29 
MTHATHA 270 37 307 10 297 3.26 
MAFIKENG 449 60 509 12 497 2.36 
LIMPOPO MUSINA 171 47 218 3 215 1.38 
GRAND TOTAL 4274 551 4825 68 4757 1.41 
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3.7 Validity and of HIV rapid test results 
In order to determine the validity and reliability of RDT against the gold standard 
ELISA in Limpopo, Mpumalanga and New Start sites, the sensitivity and 
specificity, PPV and NPV were determined (table 3.9). The positivity rate 
(prevalence) in each setting was 22.9% in Limpopo, 26% in Mpumalanga and 11% 
in New Start sites. The sensitivities of the RDT in Limpopo, Mpumalanga and New 
Start sites were 86.5% (CI: 83.9-89.4), 72.0% (CI: 64.2-79.0) and 98.0% (CI: 97.6-
98.4) respectively which indicates that 86%, 72% and 98% (CI:95%) of 
participants were identified as HIV positive. Specificity was 99.4% (98.9-99.9) both 
in LP and MP, and 98.5 5 (98.2-98.8) on New Start sites.  
 
The PPV in Limpopo, Mpumalanga and New Start sites were 98% (CI: 93.2-99.6), 
97% (CI: 91.0-99.2) and 93% (CI: 92.3-93.7) respectively and thus participants 
who tested HIV positive were likely to be HIV infected. The NPV results in 
Limpopo and Mpumalanga were 93% (CI: 90.5-95.2) and 86% were (CI: 81.3-
90.7). For New Start sites, the NPV was 99.6% (CI: 99.4-99.8).  
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Sites Limpopo (%) Mpumalanga (%) New Start sites (%) 
  
 
  
Table 3.9. Sensitivity, Specificity, PPV and NPV calculations  
Discordance rate 5.9 11 1.4 
 
Sensitivity (95% CI) 
 
86.5 (83.9 – 89.4)  
 
72.0 (64.2 – 79.0) 
 
98.0 (97.6-98.4) 
 
Specificity (95% CI) 
 
99.4 (98.9 – 99.9) 99.4 (98.9 –99.9) 98.5 (98.2-98.8) 
 
PPV (95% CI) 
 
98.1 (93.2 – 99.6) 97.0 (91.0 – 99.2) 93.0 (92.3-93.7) 
 
NPV (95% CI) 
 
93.1 (90.5 – 95.2) 86.1 (81.3 –90.7) 99.6 (99.4–99.8) 
 
Total tested 
 
457 
 
361 
 
4825 
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3.8 Association of QA with HIV discordance rate 
Logistic regression models were used to estimate the Odds Ratio (OR) and the 
95% confidence interval of the association between implementation of QA 
programme and the HIV test accuracy or the HIV discordance rate (table 3.10). 
Facilities without a QA intervention programme had an approximately 2-fold 
increased odds of HIV test discordance compared to facilities with a QA 
programme in place (crude OR 1.86, 95% CI: 1.10 – 3.12 and adjusted OR 1.90, 
95% CI:1.08 - 3.30). This association was statistically significant. The sex and age 
of the participants was not associated with discordance rate. There were no more 
variables in the study to compare and determine the barriers and/or enablers for 
accuracy of testing. These would inform future studies as they would provide 
policies and programmes with relevant data to make informed decisions. 
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Table 3.10 Impact of QA on discordance rate 
  
 
 
 
 
 
Factor    Crude 
Odds Ratio 
95% CI p-
value 
 *Adjusted 
Odds Ratio 
95% CI p-
value 
QA 
intervention 
      
   Yes  1.00 reference - 1.00 reference  
   No 1.86 1.10 – 
3.12 
0.020 1.90 1.08 - 
3.30 
0.025 
Sex       
   Female 1.00 reference  1.00 reference  
   Male 1.17 0.67 – 
2.04 
0.578 1.12 0.63 - 
2.00 
0.693 
Age  0.99 0.96 – 
1.01 
0.280 0.98 0.96 - 
1.01 
0.194 
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Table 3.11The PPV and NPV at national level (prevalence of 18.8% using Baye's 
Theorem) 
 
Predictive value 
 
National (%) 
 
 
 
PPV 
 
 
 
 
100.0 
 
NPV 
 
 
 
91.3 
 
The national prevalence (Shisana O, 2014) was used to calculate the PPV and 
NPV using Baye’s theorem (Okeh and Ugwu, 2008). The PPV was found to be 
100% (CI: 100-100) and the NPV was found to be 91% (CI: 89.04-92.96). This 
means that the probability of having a positive result if there was infection was 
100% and that of having a negative result if there was no infection was 91% (table 
3.11). 
3.9 Summary of key findings 
Sensitivity was found to be lower in the two provinces as compared to the WHO 
recommendations of 99% for first and second line RDT assays. Even in Limpopo 
where IQC was implemented the sensitivity was 86%. In Mpumalanga sensitivity 
was even lower at 72%. This means a higher probability of missing HIV positive 
clients. The PPVs in all sites were high and the NPVs were high in Limpopo and 
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New Start sites while relatively low in Mpumalanga. The PPVs calculated at 
National level was 100% while NPV was 91%. While there was an obvious decline 
in the sensitivity in the provinces, the discordant results were false negatives and 
not false positives.  
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4 CHAPTER 4: DISCUSSION 
 
4.1 Introduction 
 
The overall goal of this study was to determine the accuracy of HIV rapid testing in 
two provinces in South Africa-one in the presence and one in the absence of a 
Quality Assurance indicator (IQC), with the view of improving the accuracy of 
testing in non-laboratory settings.  
The main outcomes and the possible reasons for the results of this study are 
discussed in detail in this chapter. Firstly, the key findings are summarised, then 
discussed in detail. The significance of the research data that were collected as 
well as implications are presented. The chapter concludes with a consideration of 
the limitations of the study and highlights recommendations for future research. 
This study has advanced the field through an assessment of the state of 
implementation of a QA intervention and comparing it to a mature QA system. 
Furthermore, this study quantified the accuracy of testing and made 
recommendations based on the results.  
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4.2 Summary of key findings. 
 
The key findings of this study were as follows:  
In terms of recruitment, the study was over sampled to take into account 
administrative problems and loss of samples. The clinics enrolled more 
participants than hospitals and the HIV positivity rate was found to be higher in 
hospitals than in clinics. Though the study was oversampled, there were still 78 
participants that were excluded because they lacked critical data for the study to 
analyse, either rapid HIV results or ELISA results.   
 
The fact that 78 participants were excluded highlighted the overall problems of 
implementing QA measures in order to conduct rapid testing correctly.  The loss of 
rapid test results is a critical part of data management that needs strengthening 
through training and mentoring. Participants were enrolled and recorded but their 
rapid HIV results were not reflected in the register. The other set of results that 
was missing was the ELISA results. The missing ELISA results were due in part to 
samples clotting, which translated to improper handling of the blood samples, as 
well as results not reaching the facility from the laboratory, which could be a result 
of lack of SOPs guiding the process. These problems highlight the overall 
requirement of strengthening and or implementing key quality control measures in 
public health facilities.  
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The degree of QA implementation was associated with specific QA indicators in 
the three settings. The rate of discordant results was significantly different 
between the two provinces and when compared with New Start sites. Mpumalanga 
having the highest rate of discordant results followed by Limpopo and New Start 
sites with lowest rate of discordance. The sensitivity for New Start sites was 
highest at 98% as compared to Limpopo at 86% and Mpumalanga at 72%. The 
reported sensitivities were not in line with the WHO-recommended sensitivities of 
>99% for first line assays RDTs while specificity is at >98% for first line assays 
RDTs (WHO 2015) in the case of the public health facilities. The PPVs were very 
high among all sites as well as the NPVs. Using the sensitivities and specificities 
of Limpopo, Mpumalanga and New Start sites, at a national prevalence of 18.8%, 
the national PPV was determined to be 100% while NPV was 91.3%.  
 
4.3 Accuracy of RDT in comparison with the gold standard ELISA 
Challenges to HIV rapid testing include test sensitivity, specificity and the 
subjective interpretation of weak positive results in field settings. The WHO 
guidelines (WHO, 2009) recommend that of the available testing technologies, 
EIAs and rapid tests are the most practical and cost-effective for diagnostic 
purposes, and provide results comparable to an EIA/Western blot algorithm. 
Studies have shown that the testing algorithms using EIAs and rapid tests are as 
reliable for confirmation as western blots (WHO, 2009). In addition, compared with 
Western blots, EIAs and rapid tests are less expensive, do not require as high a 
level of technical expertise to perform and interpret, and produce fewer 
97 
 
indeterminate results (UNAIDS, 1997; UNAIDS/WHO 1999). UNAIDS and WHO 
therefore, recommend alternative testing strategies using combinations of EIAs or 
rapid tests to confirm initial reactive test results where the tests should be highly 
sensitive and specific to provide reliable detection of antibodies in a specimen.  
 
The current results show that the implementation of QA including the use of a 
process control in LP resulted in a higher sensitivity of the testing but did not reach 
the recommended sensitivity. It is possible to achieve as near to the 
recommended sensitivity as observed in New Start sites. New Start sites 
compared to LP had a wider range of QA tools implemented. The results show 
that with incremental implementation of QA tools accurate testing is feasible. The 
results also suggest that the consistent implementation and monitoring of QA can 
achieve the required objective. Where the sensitivities do not to reach the required 
target it would be useful to review current algorithms. The New Start sites followed 
more closely the recommended WHO guidelines in terms of the testing strategy. 
The decline in sensitivities in the public health sector poses a challenge of missing 
HIV positive individuals.  
 
This study has contributed to the field in that it quantified the accuracy of testing 
and made recommendations informed by the results based on sensitivities and 
specificities of the tests unlike previous studies such as the SEAD (2010) study 
that focussed on a process evaluation to identify potential problems observed 
during the HCT service provision. The SEAD study did not quantify accuracy of 
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testing though their recommendations were implementation of QA to improve 
quality of service provision. The study recommendations were focussed on 
improving the actual service of HCT rapid testing and complying with the 
processes. The SEAD study focussed on operations and analysis of VCT 
implementation in selected South African public health facilities (for example, 
availability of stop watches, compliance to incubation times, availability of test kits 
on national tender, swabs and buffers, availability of SOPs, putting gloves on 
during testing, availability of registers, etc). It aimed at identifying potential 
problems observed during HCT service provision. It may be known already that 
misclassification occurs but this thesis focuses on an intervention for the process 
control namely the Internal Quality Control (IQC) and in general QMS. This is 
compared to sites that do not have the intervention and sites that have a mature 
QA/QMS intervention. South Africa does not have this data. At the design of this 
study there was no data available for the rate of misclassification in public health 
facilities in South Africa which is why the sample size had to be based on proxy 
national prevalence. This study has provided the data on rate of misclassification. 
 
The decline in sensitivity in the field i.e. at counselling and testing sites has been 
reported in several studies and may be due to non compliance to storage and 
transportation of the test kits, lack of quality control and lack of training (Mayhood 
MK, 2008;Black V, 2009; Ramalingam S, 2002, Van den Berk GEL, 2003;Ferreira 
CJ, 2005;Plate DK, 2007; Wolpaw BJ , 2010). A decrease in sensitivity means that 
there is a higher probability that patients who are HIV positive may be missed. As 
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compared to the manufacturer's reported sensitivity of 100% per test kit and NICD 
laboratory evaluation, the New Start sensitivity remained high indicating a low 
probability of missing positive results. This will be a problem for South Africa 
based on the volumes that are tested annually though the re-testing process may 
partially mitigate the problem as evidenced by the extent of testing overall. The 
specificity, however, ranged between 99 to 100% between the 2 provinces and 
New Start sites, translating to the fact that it is highly likely that patients who tested 
HIV negative are not infected. Given the high PPVs in Limpopo, Mpumalanga and 
New Start sites, the likeli-hood of HIV diagnosis on a positive result is good. This 
will play a crucial role for the 909090 strategy. By contrast, the results are different 
between the two provinces in terms of NPV, 93%, 86% for Limpopo, Mpumalanga 
sites respectively. New Start sites had NPV of 99%. 
 
Awareness of one’s HIV status through HIV testing is an important entry point to a 
comprehensive package of care for HIV and AIDS prevention and treatment 
(NDOH, 2010). Population-level HIV testing in South Africa is among the highest 
globally, with a large proportion of South Africans knowing their HIV status. 
Shisana O, (2014) reported that in their survey, 65% of participants (n=28 997) 
knew their HIV status (Shisana O, 2014). The authors further reported that in 
2012, the total number of people who were HIV positive was estimated at 6.4 
million with over 2.5 million on treatment (Shisana O, 2014). It thus remains 
necessary to maintain high levels of testing for individual awareness of HIV status, 
and ART initiation. In addition to acting as a treatment for HIV, ART can also be 
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considered as treatment as prevention TasP(Cohen MS 2010). TasP reduces HIV 
viral load, which, in turn, decreases the likelihood of onward transmission of HIV 
(Donnell D 2010).  
 
4.4 Reliability and validity of rapid test kits 
The overall effect of reduced test sensitivity and specificity at a national level was 
calculated. The sensitivities and specificities of Limpopo, Mpumalanga and New 
Start sites were used to determine the PPV and NPV nationally with a prevalence 
of 18.8% (Shisana O, 2014). The PPV was found to be 100% while the NPV was 
lower at 91.3 %. This means that nationally, a positive result means that patients 
who test HIV positive are likely to have HIV infection. The NPV was 91% which 
means that there is a possibility that patients who test HIV negative are HIV 
infected. New Start with a mature QMS system showed high sensitivities and low 
discordant rates meaning that QA plays an important role in improving the quality 
of testing including sensitivities.  Limpopo followed and Mpumalanga had the 
lowest sensitivities and highest discordance rate. 
 
There were no reported IQC failures in the pilot programme in Limpopo and thus 
the test devices performed as expected. At commencement of the pilot 
programme, logbooks were distributed to all selected facilities to monitor 
compliance. This included monitoring the results of the HIV rapid tests conducted 
as recorded in the register. Based on the results of the reports of the monitoring 
visits, and the results of this study it was recommended that IQC be rolled out to 
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all health facilities in Limpopo and eventually throughout the country as it clearly 
improved the quality of diagnosis of HIV rapid testing in non-laboratory settings. 
The lower sensitivity nevertheless, points to the fact that despite the 
implementation of IQC it did not to address all problems likely to be associated 
with QA.  
 
4.5 Discordant Results 
Increased discordance was associated with the extent of implementation of QA as 
shown by the results of the logistic regression model (crude and adjusted). 
Facilities in Mpumalanga, which did not have a QA intervention programme had an 
approximately 2-fold increased odds of HIV test discordance compared to facilities 
in Limpopo with a QA programme in place (OR 1.86, 95% CI: 1.10 – 3.12). This 
association was statistically significant. The gender and age of the participants 
was not associated with discordance rate. Mpumalanga province which had the 
highest level of discordance had limited evidence of QA implementation as 
compared to Limpopo province where there was evidence of IQC implementation 
for a period of two years. New Start sites, where the discordance was lowest, had 
a mature system with the highest level of QA implementation including formal QA 
systems such as IQC, EQA and QA managers. 
 
The rate of discordance differed within facilities in Limpopo which implies that even 
though all the facilities were implementing IQC, there may still be some challenges 
that are affecting the results of diagnosis. This means that the implementation of 
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QA measures need to be continually monitored and supported by training and 
mentoring to ensure good quality diagnosis 
4.6 HIV Diagnosis 
The overall characteristics for the sites were similar in both provinces. There were 
only certain differences that did not affect the results. The clinics enrolled most of 
the participants as compared to hospitals generally. This was due to the fact that 
clinics were the first point of entry for health care including HCT. Patients who 
presented at hospitals were originally referred from the clinics due to complications 
and complexity of the cases. The patients diagnosed for HIV at hospitals were 
likely to be chronically ill with poorer outcomes and this might explain why the HIV 
positivity rate was higher in hospitals as compared to clinics. The positivity rate 
was also higher in Mpumalanga as compared to Limpopo and New Start sites. 
This also agrees with published data by Shisana O (2014) regarding the positivity 
rates of the different provinces. 
 
4.7 Misclassification 
In this study there was a decline in sensitivity that resulted in false negative 
results. To a lesser extent, some false positive results were also identified in New 
Start sites. False negative results accounted for all the discordant results in LP 
and MP. Some of the reasons for false negative results include ongoing 
seroconversion, divergent HIV strain, inhibitory factors in specimen, insufficient 
specimen added, too much buffer, storage and transportation and possible 
manufacturing defects (WHO, 2015). While access to HIV diagnosis is life-saving; 
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the use of rapid diagnostic tests in combination may be vulnerable to wrongly 
diagnosing HIV infection when both assays give a false positive result (Shanks L, 
2013, Cruccitti, 2011; Baveewo S, 2012). This has been documented and is 
reported to be caused by predominantly, serological cross reactivity (Kleinman et 
al., Gray RH, 2007; Anzala O, 2008). False positive diagnosis can result in 
patients being placed on treatment unnecessarily which translates to wasting of 
resources and devastation on the misdiagnosed patient. False positive results are 
found to be higher in low HIV prevalence contexts as even the rapid tests with high 
sensitivity can perform poorly. False positive diagnosis was also reported in 
resource limited settings (Shanks L, 2013). Other reasons for misclassification are 
linked to administrative errors, test storage and transport conditions, poor quality 
control, lack of training and supervision of staff, limitations of the assay itself, sub-
optimal national testing algorithms, workload, SOPs not being followed, 
contaminating proteins in specimen and possible manufacturing defects (Shanks 
L, 2013; WHO, 2015). 
 
4.8 South Africa’s Future for QA of RDT 
In order to strengthen its HIV RDT programmes, South Africa needs to review and 
strengthen the current HIV programme plans and standards with regards to 
incorporation of QA programmes. The HIV testing programme already has high 
engagement with the Ministry of Health, the National reference laboratory (NICD), 
the programme managers and non-governmental implementing partners as 
recommended by WHO (WHO, 2015). The national testing policy has been 
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revised and this provides guidance to implementation of RDTs including improved 
quality assurance programmes and algorithms to minimize discordance (NDOH, 
2016). This policy needs to be implemented in all public health facilities, private 
sector and implementing partners. Implementation of the approved standard 
operating procedures and job aides is of critical importance. 
 
Since the study shows that accuracy of RDTs is improved by the implementation 
of QA interventions accompanied by appropriate training and certification, and 
monitoring of the use of RDTs, plans need to be put in place to gradually phase in 
implementation at  all sites. Introduction of IQC should be rolled out in all Public 
health facilities and other sites that implement RDTs. Furthermore, EQA methods 
should also be implemented to complement IQC. These should include PT 
methods where there is capacity within the laboratories for assessments of the 
panels, re-testing methods, especially in non-governmental organizations where 
the through-put is not very high and assessments through site visits including 
observation methods. Assessment methods may include the use of tools such as 
the stepwise process for improving the quality of HIV rapid testing (SPI-RT) 
checklist. The checklist provides the following:  
• a solid foundation for ensuring the quality of testing in Public health facilities  
• a guideline to evaluate a RT site against the requirement for quality 
improvement 
• a guideline for the development of policies and procedures 
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It is crucial that South Africa implements these EQA methods to identify and 
prevent misdiagnosis. Implementation of an HIV rapid testing quality improvement 
initiative (RTQII) aims to ensure quality of testing and expand upon current in 
country HIV rapid testing quality improvement work (http://www.rtqi.com.)  
 
RTQII comprises of the following 5 key action areas: 
• Policy engagement 
• Human Resources 
• PT programmes 
• Standardised register data collection tool 
• Post market surveillance 
 
Strengthening of data collection processes, data analysis, timely reporting of 
results to sites followed by corrective action is crucial for monitoring and evaluation 
of the programme. Strengthening supply chain processes is important to ensure 
availability of testing kits at all times.  
 
Individuals on ART are not recommended for routine re testing. This is because 
the sensitivity of RDTs and laboratory tests can be reduced by exposure to ART 
because of viral suppression, making this method unreliable for confirming a 
positive diagnosis. Confirmation for patients on ART requires antigen tests such as 
the polymerase chain reaction (PCR).   
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4.9 Limitations 
The limitations of the study were as follows: 
 
1. The main limitation of the study was time differences in New Start data and 
the study prospective data for LP and MP as the study could not provide a 
direct comparison of results between all sites on a real time basis.  
 
2. The study was not a randomised cluster assessment design within LP in 
order to avoid a problem of contamination as most facilities were either 
already implementing QA or in the process of initiating implementation, the 
study was not fully blinded in Limpopo. Other study designs were also 
explored such as an impact evaluation design, matched control design, 
cohort, a cluster randomised control design, and a stepped wedge RCT 
study. A cross sectional design was best suited for this study. 
 
3. There is also potential bias in comparing LP and MP when determining 
whether the intervention of IQC was effective in improving the accuracy of 
testing. The assumptions are that facilities in both provinces are staffed by 
the same categories of staff, hierarchy of reporting was similar, and 
processes were the same. The only differences being the implementation 
of QA and IQC specifically. 
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4. Potential bias in convenient sampling in both Provinces but based on 
practical considerations such as accessible sites and proximity to 
laboratory services 
 
5. Potential bias in reading and interpreting results as the study design does 
not provide for inter-reader variability, for example, as diagnosis was 
determined by one end-user at a given time as they received the results. 
This is standard practice in routine testing 
 
6. Potential bias using two different NHLS labs. Assumption was that the 
performance of both labs was not different. 
 
7. Use of 4th generation testing (ELISA) as a final diagnosis compared to 
RTD. Given the maturity of the HIV epidemic, it is likely that acute 
infections are a small proportion of the HIV infected population and would 
not explain extent of loss of sensitivity.   
 
8. Further analysis by OD signal value of ELISA and Western blot banding 
pattern could have been useful to understand the causes of RT false 
negatives other than the operator.   
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5 CHAPTER 5 CONCLUSION 
The conclusion is based on the results and discussion of the study objectives. 
The implementation of QA measures plays a crucial role in the accurate 
diagnosis of HIV rapid testing. The accuracy of HIV diagnosis is improved by 
implementation of QA. This is seen in the higher sensitivities of New Start and 
Limpopo sites. Based on the results of the study, it is concluded that even 
though the sensitivity of New Start and Mpumalanga rapid testing did not meet 
the WHO criteria for sensitivities in the field, implementation of QA plays a 
critical role on the improvement of accuracy of rapid testing as also seen in 
New Start where sensitivity was very high. South Africa must implement 
several aspects of QA, including PT methods of EQA, training, mentoring and 
supervision, this increases the accuracy of testing and the sensitivities of the 
tests. Increasing sensitivities will also play a crucial role in the event of a 
possible move towards self-testing and the move towards the 909090 strategy. 
Should the sensitivities not reach the recommended levels in the presence of a 
QMS implementation, the algorithms must be re- evaluated. Limitations of the 
study must be taken into consideration in order to guide more studies regarding 
quality assurance of rapid diagnostic test kits. 
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5.1 Recommendations 
• Implementation of quality management systems through a quality 
assurance quality improvement activity such as the PEPFAR-supported 
Quality Improvement Initiative: Stepwise Process for Improving HIV rapid 
testing that has a series of steps including monitoring of implementation 
(http://www.pepfar.gov/documents/organization/217761.pdf) 
• Implementation of the new South African HTS Policy 
• Improved use of site data such as IQC and PT as part of the passive post-
marketing surveillance to detect any technical problems with the device and 
limit false negative and positive results. 
• Review of test algorithm if it is found that despite improvements in QA 
implementation performance is still less than recommended 
sensitivity/specificity. 
• Adequate on-going training, refresher training and supportive supervision of 
HIV testing providers, with requirement for certification should be in place.  
• Implementation of the WHO guidelines including 
o Repeat HIV rapid testing in case of discordant results  
o Replace the use of the laboratory-based tiebreaker ELISA testing 
with referral for laboratory-based diagnostic testing per NHLS 
guidelines 
• Explore the use of electronic readers to improve consistency of reading. 
Explore future technologies such as m-health and cell phone technology for 
ensuring quality of testing.
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6 CHAPTER 6: APPENDICES 
APPENDIX 1: LOG BOOK FOR DATA COLLECTION 
NATIONAL HIV RAPID TESTING QUALITY ASSURANCE LOGBOOK 
Name of Counsellor :                                                                                   Facility:                                                                           Province: 
Number 
Client/patient 
code  
Age 
(years) Gender 
Date 
tested 
1st Test 
kit name 
 
 
2nd Test 
kit name 
 
 
Result 
given to 
client Observed 
Registered Nurse 
Signature 
Specimen for HIV Elisa 
(Tie Breaker) 
Lot No Lot No 
Exp Date Exp Date 
1   M   F  R   NR   
INV 
R   NR   
INV 
P       N       
IND 
Y       N   
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Page Total        
Total Reactive/Positive 
Total Non Reactive/negative 
Total invalid/indeterminate 
R= Reactive, NR=Non-Reactive and INV=Invalid P=Positive, N=Negative, and IND= Indeterminate 
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APPENDIX 2: ETHICS CLEARANCE 
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APPENDIX 3: STUDY INFORMATION SHEET 
INFORMATION DOCUMENT (will be translated in the local languages should 
the need arise) 
Study title: Comparison of accuracy of HIV diagnosis between rapid HIV test 
kits conducted in non-laboratory settings and laboratory-based ELISA 
methods in South Africa 
Greeting and Introduction: 
Good day, my name is Thato Chidarikire. I am a PhD student from the University 
of the Witwatersrand. We are doing research on the comparison of accuracy of 
diagnosis between rapid HIV test kits conducted in non-laboratory settings(such as 
this clinic where only a finger prick is rapidly analysed) and laboratory–based 
ELISA methods. Research is a process that one undertakes in order to answer a 
particular question. In this study, we want to find out if the accuracy of HIV 
diagnosis between the rapid HIV test kits and the laboratory-based ELISA method 
is the same or of acceptable standards so that doctors don’t have to refer HIV test 
results to the laboratory for confirmation when a patient has come to the facility 
and can rely fully on HIV rapid test kits results. This will shorten the time it takes to 
wait for laboratory results especially for patients who need to be fast tracked in to 
the treatment programme. This study is being conducted in selected public health 
facilities in Limpopo and Mpumalanga provinces. 
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Invitation to participate:  We would like to request for your participation in the 
study as this would greatly assist us in terms of finding an answer to this very 
important question. 
What is involved in the study – This study will be conducted in selected public 
health facilities in Limpopo and Mpumalanga provinces. After pre test counselling 
and signing of the informed consent form, the study participants will be offered a 
rapid HIV test which will be conducted following the national HCT guidelines where 
you will be screened for HIV with a rapid HIV test kit and if your results are HIV 
negative you will be reported as HIV negative. If your results are HIV positive, you 
will be confirmed with another HIV rapid test kit. If your results are HIV positive you 
will be reported as HIV positive and you will be referred for further management.  
If you agree to participate the following procedures will carried out. A drop of blood 
will be drawn from you using a finger prick method. Blood will be tested for HIV 
using the rapid HIV test kits. Following the rapid test, irrespective of your HIV 
status, whole blood (about 5ml on 1 teaspoonful from your arm) will be collected 
from you for an ELISA test at the NICD laboratory closest to the clinic that you 
attend. You will only be in the study for the, although the total duration of the study 
in the facilities will be six months. The procedure for HIV counselling and testing 
and drawing of venous blood may take approximately 30 minutes. All participants 
will be given their HIV test results for both the rapid method and the ELISA 
method. A total of 1200 (600 per province) participants will be involved in the 
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study. If you need further counselling and support this will be provided to you at 
the facilities through the current services. 
Risks 
There will be no risk for you if you participate in the study. Blood will be collected 
by a finger prick (1-2 drops) and by venesection (5ml). This may cause brief minor 
physical discomfort to your finger and at the site of the vein. 
Benefits: There are no direct benefits for participating in the study but taking an 
HIV test is very beneficial as it will let you know your HIV status so that you may 
make informed decisions based on your HIV status including early access to 
treatment if needed.  You will receive all information on the study while you are 
involved in it and after the results are available. 
Participation is voluntary: Your participation in this study is completely voluntary. 
If you refuse to participate in the study, there will be no penalties or loss of any 
benefits that you may be otherwise entitled to. You will still receive your standard 
medical care. You may also discontinue your participation in this study at any point 
without any penalties or loss to benefits that you were otherwise entitled to 
receive. 
Reimbursements: There will be no reimbursement for participation in this study.  
Confidentiality: Efforts will be made to keep all personal information confidential.  
Codes will be used on the data collection forms and these will be linked to patient 
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names in a separate record sheet kept under lock and key and only accessible to 
the researcher and supervisor. Data will be analysed as grouped data and 
presented as such. Even if results are published, confidentiality will still be 
maintained.  
For further information related to the study, you may contact me 
at the following contacts: Ms Thato Chidarikire, Tel: +27 12 395 
9153 or Chidat@health.gov.za/chidarikiret@gmail.com 
For reporting of complaints or problems, you may contact Ms AnisaKeshav, 
University of the Witwatersrand Human Ethics Committee (HREC) on the following 
contacts: Ms AnisaKeshav, Tel: +27 11 717 1234 or anisa.keshav@wits.ac.za 
 
Thank You 
Yours Sincerely, 
Thato Chidarikire 
University of the Witwatersrand, South Africa 
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APPENDIX 4: STUDY INFORMED CONSENT FORM 
INFORMED CONSENT FORM 
Study title: Comparison of accuracy of HIV diagnosis between rapid HIV test kits 
conducted in non-laboratory settings and laboratory-based ELISA methods in 
South Africa 
I understand that I have been asked to participate in the abovementioned study. I 
have heard the aims and of the Research Study that is proposed and I was given 
an opportunity to ask question in order to understand the study fully. 
I understand that taking part in this research study is completely voluntary, that is, 
of my own choice and I know that I may withdraw from the study at any point 
without being penalized.  
I understand that the researchers will make every effort to keep personal 
information confidential. 
1. I hereby agree to participate in this research study as per the information 
letter 
……………………………………………  ………………………………. 
Name of participant      Place 
……………………………………………       ………………………………. 
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Signature of participant     Date 
……………………………………………  ……………………………… 
Name of witness      Place 
……………………………       .............................................
  
Signature of witness     Date 
………………………………………  ................................   
Name of Health Care Worker   Signature and Date 
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APPENDIX5: APPROVAL FROM LIMPOPO PROVINCE 
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APPENDIX 6: APPROVAL FROM MPUMALANGA PROVINCE 
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